

AUTHOR INDEX FOR VOLUME 41

A

- Adham, N., Romanienko, P., Hartig, P., Weinshank, R. L., Branchek, T. The rat 5-hydroxytryptamine_{1D} β receptor is the species homologue of the human 5-hydroxytryptamine_{1D} β receptor, 1
- Albuquerque, E. X. *see* Alkondon, M., 802
- Alkondon, M., Pereira, E. F. R., Wonnacott, S., and Albuquerque, E. X. Blockade of nicotinic currents in hippocampal neurons defines methyllycaconitine as a potent and specific receptor antagonist, 802
- Allan, P. W., *see* Parker, W. B., 245
- Amico, C., *see* Condorelli, D. F., 660
- Amiet, R. G., *see* Sobol, M. M., 8
- Anderson, S. A., *see* Fong, T. M., 24
- Andries, K., *see* Debyser, Z., 203
- Appell, K. C., Fragale, B. J., Loscig, J., Singh, S., and Tomczuk, B. E. Antagonists that demonstrate species differences in neurokinin-1 receptors, 772
- Arlinghaus, R. B., *see* Sastry, J. K., 441
- Arnett, G., *see* Parker, W. B., 245
- Atkinson, B. N., and Minneman, K. P. Preferential desensitization of β -versus α_2 -Adrenergic receptors accelerates loss of response to norepinephrine in primary glial cultures, 688
- Audigier, Y., *see* Varrault, A., 999
- Aylwin, M. L., and White, M. M. Forskolin acts as a noncompetitive inhibitor of nicotinic acetylcholine receptors, 908
- Azzazro, A. J., *see* Vrana, S. L., 839

B

- Baba, M., *see* Debyser, Z., 963
- Bachur, N. R., Yu, F., Johnson, R., Hickey, R., Wu, Y., and Malkas, L. Helicase inhibition by anthracycline anticancer agents, 993
- Bailly, C., O'Huigin, C., Houssin, R., Colson, P., Houssier, C., Rivalle, C., Bisagni, E., Henichart, J.-P., and Waring, M. J. DNA-binding properties of a distamycin-ellipticine hybrid molecule, 845
- Bandiera, S., *see* Cadario, B. J., 981
- Barber, D. L., Ganz, M. B., Bongiorno, P. B., and Strader, C. D. Mutant constructs of the β -adrenergic receptor that are uncoupled from adenylyl cyclase retain functional activation of Na-H exchange, 1056
- Barden, N., *see* Pepin, M.-C., 1016
- Baska, R., *see* Norman, J. A., 53
- Beaumont, A., *see* Soleilhac, J. M., 609
- Beaune, P. H., *see* Shimada, T., 856
- Becker, G. W., *see* Wrighton, S. A., 76
- Begleiter, A., Robotham, E., and Leith, M. K. Role of NAD (P)⁺H: (quinone acceptor) oxidoreductase (DT-diaphorase) in activation of mitomycin C under hypoxia, 677
- Begleiter, A., *see* Yang, W. Z., 625
- Bellward, G. D., *see* Cadario, B. J., 981
- Bennett, C. F., Chiang, M.-Y., Chan, H., Shoemaker, J. E. E., and Mirabelli, C. K. Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides, 1023
- Bennett, L. L., Jr, *see* Parker, W. B., 245
- Ber, E., *see* Cascieri, M. A., 1096
- Bergeron, F., *see* Durieux, C., 1089
- Berman, H. A., Leonard, K. Interaction of tetrahydroaminoacridine with acetylcholinesterase and butyrylcholinesterase, 412
- Bielawska, A. E., *see* Werner, M. H., 382
- Bijsterbosch, M. K., Van Berkel, T. J. C. Lactosylated high density lipoprotein: A potential carrier for the site-specific delivery of

drugs to parenchymal liver cells, 404

- Bisagni, E., *see* Bailly, C., 845
- Black, W., *see* Wrighton, S. A., 76
- Bleakman, D., *see* Brorson, J. R., 603
- Boarder, M. R., *see* Murrin, R. J. A., 561
- Bobichon, C., *see* Randle, J. C. R., 337
- Bochaert, J., *see* Rouot, B., 273
- Bockaert, J., *see* Ouadid, H., 346
- Bockaert, J., *see* Varrault, A., 999
- Bongiorno, P. B., *see* Barber, D. L., 1056
- Bonin, H., *see* Suzuki, T., 542
- Boulay, G., Servant, G., Luong, T.-T., Escher, E., and Guillemette, G. Modulation of angiotensin II binding affinity by allosteric interaction of polyvinyl sulfate with an intracellular domain of the DuP-753-sensitive angiotensin II receptor of bovine adrenal glomerulosa, 809
- Bouvier, M., *see* Suzuki, T., 542
- Brach, M. A., Kharbanda, S. M., Herrmann, F., Kufe, D. W. Activation of the transcription factor κ B in human KG-1 myeloid leukemia cells treated with 1- β -D-arabinofuranosylcytosine, 60
- Branch, R. A., *see* Fleming, C. M., 975
- Branchek, T., *see* Adham, N., 1
- Brann, M. R., *see* Wess, J., 369
- Brett, R. S., *see* Dilger, J. P., 127
- Bridges, E. G., *see* Weidner, D. A., 252
- Bronson, J. J., *see* Ho, H.-T., 197
- Brorson, J. R., Bleakman, D., Chard, P. S., and Miller, R. J. Calcium directly permeates kainate/ α -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors in cultured cerebellar Purkinje neurons, 603
- Brown, J. A., *see* Machida, C. A., 652
- Brown, L. M., *see* Leslie, S. W., 308
- Budnitz, D., *see* Hartzell, H. C., 880
- Burch, R. M., *see* Sullivan, J. P., 38
- Burcher, E., *see* Geraghty, D. P., 147
- Burchman, P. C., *see* Harman, A. W., 665

C

- Cadario, B. J., Bellward, G. D., Bandiera, S., Chang, T. K. H., Ko, W. W., Lemieux, E., and Pak, R. C. K. Imprinting of hepatic microsomal cytochrome P-450 enzyme activities and cytochrome P-450IIC11 by peripubertal administration of testosterone in female rats, 981
- Cantoni, O., Sestili, P., Guidarelli, A., Giacomoni, P. U., and Cattabeni, F. Effects of L-histidine on hydrogen peroxide-induced DNA damage and cytotoxicity in cultured mammalian cells, 969
- Carling, R. W., *see* Foster, A. C., 914, 923
- Carrell, H. L., *see* Punzi, J. S., 569
- Carrett, J., *see* Rouot, B., 273
- Carver, G. T., *see* Overby, L. H., 1039
- Casabona, G., *see* Condorelli, D. F., 660
- Cascieri, M. A., Huang, R.-R. C., Fong, T. M., Cheung, A. H., Sadowski, S., Ber, E., and Strader, C. D. Determination of the amino acid residues in Substance P conferring selectivity and specificity for in the rat neurokinin receptors, 1096
- Casza, J. P., *see* Yun, Y.-P., 474
- Cattabeni, F., *see* Cantoni, O., 969
- Cha, J.-H. J., Makowiec, R. L., Penney, J. B., and Young, A. B. Multiple states of rat brain (RS)- α -amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors as revealed by quantitative autoradiography, 832

- Chambers, T. C., Zheng, B., and Kuo, J. F. Regulation by phorbol ester and protein kinase C inhibitors, and by a protein phosphatase inhibitor (okadaic acid), of P-glycoprotein phosphorylation and relationship to drug accumulation in multi-drug human KB cells, 1008
- Chan, H., *see* Bennett, C. F., 1023
- Chang, T. K. H., *see* Cadario, B. J., 981
- Changeux, J. P., *see* Chatrenet, B., 1100
- Chao, C. C.-K., Huang, Y.-T., Ma, C. M., Chou, W.-Y., Lin-Chao, S. Overexpression of glutathione S-transferase and elevation of thiol pools in a multidrug-resistant human colon cancer cell line, 69
- Chao, E. S., *see* Jansing, R. L., 209
- Charbert, C., *see* Rouot, B., 273
- Chard, P. S., *see* Brorson, J. R., 603
- Charleson, P., *see* Charleson, S., 873
- Charleson, P., *see* Mancini, J. A., 267
- Charleson, S., Prasit, P., Léger, S., Gillard, J. W., Vickers, P. J., Mancini, J. A., Charleson, P., Guay, J., Ford-Hutchinson, A. W., and Evans, J. F. Characterization of a 5-lipoxygenase-activating protein binding assay: Correlation of affinity for 5-lipoxygenase-activating protein with leukotriene synthesis inhibition, 873
- Charnet, P., Labarca, C., and Lester, H. A. Structures of the γ -less nicotinic acetylcholine receptor: Learning from omission, 708
- Charpentier, N., *see* Rouot, B., 273
- Chatrenet, B., Kotzyba-Hibert, F., Mulle, C., Changeux, J. P., Goeldner, M. P., and Hirth, C. Photoactivatable agonist of the nicotinic acetylcholine receptor: Potential probe to characterize the structural transitions of the acetylcholine binding site in different states of the receptor, 1100
- Chen, L.-I., *see* Kong, X.-B., 237
- Cheng, Y.-C., *see* Gao, W. Y., 223
- Cheng, Y.-C., *see* Mellors, J. W., 446
- Cheung, A. H., Huang, R.-R. C., and Strader, C. D. Involvement of specific hydrophobic, but no hydrophilic, amino acids in the third intracellular loop of the β -adrenergic receptor in the activation of G_s , 1061
- Cheung, A. H., *see* Cascieri, M. A., 1096
- Chiang, M.-Y., *see* Bennett, C. F., 1023
- Chou, T.-C., *see* Kong, X.-B., 237
- Chou, W. Y., *see* Chao, C. C.-K., 69
- Ciszewska, G., *see* Kong, X.-B., 237
- Clarke, S. D., *see* Kletzien, R. F., 393
- Clifford, D., *see* Zorumski, C. F., 931
- Colson, P., *see* Bailly, C., 845
- Comer, K. A., and Falany, C. N. Immunological characterization of dehydroepiandrosterone sulfotransferase from human liver and adrenal, 645
- Cometta-Morini, C., Maguire, P. A., Loew, G. H. Molecular determinants of μ receptor recognition for the fentanyl class of compounds, 185
- Condorelli, D. F., Dell'Albani, P., Amico, C., Casabona, G., Genazzani, A. A., Sortino, M. A., and Nicoletti, F. Developmental profile of metabotropic glutamate receptor mRNA in rat brain, 660
- Connor, J. R., *see* Sullivan, J. P., 38
- Coon, M. J., *see* Roberts, E. S., 427
- Cooper, D. M. F., *see* Garritsen, A., 743
- Coppolino, M. G., *see* Mancini, J. A., 267
- Cordi, A., *see* Randle, J. C. R., 337
- Corringer, P.-J., *see* Durieux, C., 1089
- Costa, E., *see* Kiedrowski, L., 779
- Costa, E., *see* Olasmaa, M., 456
- Costa, T., Ogino, Y., Munson, P. J., Onaran, O., and Rodbard, D. Drug efficacy at guanine nucleotide-binding regulatory protein-linked receptors: Thermodynamic interpretation of negative antagonism and of receptor activity in the absence of ligand, 549
- Cote, T. R., *see* Crawford, K. W., 154
- Cotelle, P., *see* Goossens, J.-F., 104
- Cowan, K. H., *see* Townsend, A. J., 230
- Crane, M. R., Hughes, M., O'Hanley, P. D., and Waldman, S. A. Identification of two affinity states of low affinity receptors for *Escherichia coli* heat-stable enterotoxin: Correlation of occupation of lower affinity state with guanylate cyclase activation, 1073
- Crawford, K. W., Frey, E. A., Cote, T. E. Angiotensin II receptor recognized by DuP753 regulates two distinct guanine nucleotide-binding protein signaling pathways, 154
- Cretton, E. M., *see* Weidner, D. A., 252
- Curras, M. C., and Dingleline, R. Selectivity of amino acid transmitters acting at N-methyl-D-aspartate and amino-3-hydroxy-5-methyl-4-isoxazole-propionate receptors, 520
- Curutchet, P., *see* Randle, J. C. R., 337
- Cutting, G., *see* Shimada, S., 683

D

- Dage, R. C., *see* Rampe, D., 599
- Daly, J. W., *see* Hide, I., 352
- Daly, J. W., *see* Soergel, D. G., 487
- Daniels, A. J., Matthews, J. E., Viveros, O. H., and Lazarowski, E. R. Characterization of the neuropeptide Y-induced intracellular calcium release in human erythroleukemic cells, 767
- Datta, R., Kharbanda, S., Kufe, D. W. Transcriptional and posttranscriptional regulation of H1 histone gene expression by 1- β -D-arabinofuranosylcytosine, 64
- Daujat, M., *see* Pichard, L., 1047
- Dayton, J. S., Turka, L. A., Thompson, C. B., and Mitchell, B. S. Comparison of the effects of mizoribine with those of azathioprine, 6-mercaptopurine, and mycophenolic acid on T lymphocyte proliferation and purine ribonucleotide metabolism, 671
- De Boeck, H., *see* Ho, H.-T., 197
- Debyser, Z., Pauwels, R., Andries, K., Desmyter, J., Engelborghs, Y., Janssen, P. A. J., De Clercq, E. Allosteric inhibition of human immunodeficiency virus type 1 reverse transcriptase by tetrahydroimidazo[4,5,1-*jk*][1,4] benzodiazepin-2(1*H*)-one and -thione compounds, 203
- Debyser, Z., Pauwels, R., Baba, M., Desmyter, J., and De Clercq, E. Common features in the interaction of tetrahydroimidazo[4,5,1-*jk*][1,4]benzodiazepin-2(1*H*)-one and -thione and 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives with the human immunodeficiency virus type 1 reverse transcriptase, 963
- De Carvalho, L. P., *see* Randle, J. C. R., 337
- De Clercq, E., *see* Debyser, Z., 203, 963
- Deery, W. J., *see* Pasquali, D., 163
- DeGray, J. A., *see* Knecht, K. T., 934
- Dell'Albani, P., *see* Condorelli, D. F., 660
- Del Ræio, R. M., *see* Lerma, J., 217
- DePriest, S., *see* Romano, C., 785
- Desmyter, J., *see* Debyser, Z., 203, 963
- Dickel, D., *see* Schwanstecher, D., 480
- Dilella, A. G., *see* Elshourbagy, N. A., 465
- Dilger, J. P., Brett, R. S., Lesko, L. A. Effects of isoflurane on acetylcholine receptor channels. 1. Single-channel currents, 127
- Dingleline, R., *see* Curras, M. C., 520
- Domergue, J., *see* Pichard, L., 1047
- Domin, B. A., Mahony, W. B., Koszalka, G. W., Porter, D. J. T., Hajian, G., and Zimmerman, T. P. Membrane permeation characteristics of 5'-modified thymidine analogs, 950
- Donald, A. E., *see* Foster, A. C., 914
- Donevan, S. D., Jones, S. M., and Rogawski, M. A. Arcaine blocks N-Methyl-D-aspartate receptor responses by an open channel mechanism: Whole-cell and single-channel recording studies in cultured hippocampal neurons, 727
- D'Orleans-Juste, P., *see* Warner, T. D., 399
- D'Santos, C. S., Gatti, A., Poyner, D. R., and Hanley, M. R. Stimulation of adenylate cyclase by amylin in CHO-K1 cells, 894
- Duax, W. L., *see* Punzi, J. S., 569
- Ducos, B., *see* Durieux, C., 1089
- Dumuis, A., *see* Ouadid, H., 346

- Durieux, C., Ruiz-Gayo, M., Corringier, P.-J., Bergeron, F., Ducos, B., and Roques, B. P. [^3H]pBC 246, a suitable probe for studying cholecystokinin-B receptors: Binding characteristics in rodent brains and comparison with [^3H]SNF 8702, 1089
- Dürr, U., *see* Grimminger, F., 757
- Dutschman, G. E., *see* Mellors, J. W., 446
- Duvvuri, P., *see* Valenzuela, C. F., 331

E

- Edgar, P. P., and Schwartz, R. D. Functionally relevant γ -aminobutyric acid_A receptors: Equivalence between receptor affinity (K_d) and potency (EC_{50})?, 1124
- Egan, W., *see* Gao, W. Y., 223
- Ehlert, F. J., *see* Thomas, E. A., 718
- Elshourbagy, N. A., Lee, J. A., Korman, D. R., Nuthalaganti, P., Sylvester, D. R., Dilella, A. G., Sutiphong, J. A. and Kumar, C. S. Molecular cloning and characterization of the major endothelin receptor subtype in porcine cerebellum, 465
- Engelborghs, Y., *see* Debyser, Z., 203
- Entzeroth, M., *see* Wienen, W., 1081
- Escher, E., *see* Boulay, G., 809
- Eva, C., *see* Krause, J., 817
- Evans, J. F., *see* Charleson, S., 873
- Evans, J. F., *see* Mancini, J. A., 267

F

- Fabre, I., *see* Pichard, L., 1047
- Falany, C. N., *see* Comer, K. A., 645
- Farber, J. L., *see* Glascott, P. A., 1155
- Farquhar, D., *see* Sastry, J. K., 441
- Feuerstein, G., *see* Yue, T.-L., 281
- Ficheux, M., *see* Soleilhac, J. M., 609
- Fleming, C. M., Branch, R. A., Wilkinson, G. R., and Guengerich, F. P. Human liver microsomal *N*-hydroxylation of dapsone by cytochrome P-450A4, 975
- Flocco, M. M., *see* Punzi, J. S., 569
- Flores, C. M., Rogers, S. W., Pabreza, L. A., Wolfe, B. B., Kellar, K. J. A subtype of nicotinic cholinergic receptor in rat brain is composed of $\alpha 4$ and $\beta 2$ subunits and is up-regulated by chronic nicotine treatment, 31
- Flynn, D. D., Vaishnav, A. A., and Mash, D. C. Interactions of cocaine with primary and secondary recognition sites on muscarinic receptors, 736
- Fong, T. M., Anderson, S. A., Yu, H., Huang, R.-R. C., Strader, C. D. Differential activation of intracellular effector by two isoforms of human neurokinin-1 receptor, 24
- Fong, T. M., *see* Cascieri, M. A., 1096
- Ford-Hutchinson, A. W., *see* Charleson, S., 873
- Förstermann, U., *see* Mitchell, J. A., 1163
- Förstermann, U., *see* Schmidt, H. H. W., 615
- Förstermann, U., *see* Warner, T. D., 399
- Foster, A. C., Kemp, J. A., Leeson, P. D., Grimwood, S., Donald, A. E., Marshall, G. R., Priestley, T., Smith, J. D., and Carling, R. W. Kynurenic acid analogues with improved affinity and selectivity for the glycine site on the *N*-methyl-D-aspartate receptor from rat brain, 914
- Foster, A. C., *see* Foster, A. C., 923
- Fournié-Zaluski, C., *see* Soleilhac, J. M., 609
- Fragale, B. J., *see* Appell, K. C., 772
- Franklin, P. H., Murray, T. F. High affinity [^3H]dextrorphan binding in rat brain is localized to a noncompetitive antagonist site of the activated *N*-methyl-D-aspartate receptor-cation channel, 134
- Frey, E. A., *see* Crawford, K. W., 154
- Friedman, E., *see* Yue, T.-L., 281
- Frielle, T., *see* Suzuki, T., 542
- Fulmer Shealy, Y., *see* Parker, W. B., 245

G

- Ganz, M. B., *see* Barber, D. L., 1056
- Gao, W.-Y., Han, F.-S., Storm, C., Egan, W., Cheng, Y.-C. Phosphorothioate oligonucleotides are inhibitors of human DNA polymerases and RNase H: Implications for antisense technology, 223
- Garritsen, A., Zhang, Y., and Cooper, D. M. F. Purinergic receptor regulation of signal transduction in NCB-20 cells, 743
- Gatti, A., *see* D'Santos, C. S., 894
- Gautier, J.-C., *see* Shimada, T., 856
- Gdula, D., *see* Wess, J., 369
- Genazzani, A. A., *see* Condorelli, D. F., 660
- Geraghty, D. P., Mussap, C. J., Burcher, E. Radioiodinated substance P, neurokinin A, and eledoisin bind predominantly to NK1 receptors in guinea pig lung, 147
- Gescher, A., *see* Hyland, R., 259
- Giacomoni, P. U., *see* Cantoni, O., 969
- Gilfor, E., *see* Glascott, P. A., 1155
- Gillard, J. W., *see* Charleson, S., 873
- Gillard, J. W., *see* Mancini, J. A., 267
- Glascott, P. A., Jr., Gilfor, E., and Farber, J. L. Effects of vitamin E on the killing of cultured hepatocytes by *tert*-butyl hydroperoxide, 1155
- Gleason, M. M., *see* Yue, T.-L., 281
- Glossmann, H., *see* Knaus, H.-G., 298
- Glusker, J. P., *see* Punzi, J. S., 569
- Goeldner, M. P., *see* Chatrenet, B., 1100
- Goldmann, S., *see* Zheng, W., 535
- Gommeren, W., *see* Leysen, J. E., 494
- Goossens, J.-F., Pommery, N., Lohez, M., Pommery, J., Helbecque, N., Cotellet, P., Lhermitte, M., Henichart, J.-P. Antagonistic effect of vasoactive intestinal peptide fragment, vasoactive intestinal peptide(1-11) on guinea pig trachea smooth muscle relaxation, 104
- Govindan, M. V., *see* Pepin, M.-C., 1016
- Grace, K. J. S., Medina, M., Jacobs, R. S., and Wilson, L. Selective inhibition of cytokinesis in sea urchin embryos by the marine natural product pseudopterolide, 631
- Green, M. D., *see* Sobol, M. M., 8
- Green, S. A., Holt, B. D., and Liggett, S. B. β_1 - and β_2 -adrenergic receptors display subtype-selective coupling to G_s , 889
- Griffin, J. E., *see* Punzi, J. S., 569
- Griffin, M. T., *see* Thomas, E. A., 718
- Grimminger, F., Dürr, U., and Seeger, W. Ligand-operated synthesis of 4-series and 5-series leukotrienes in human neutrophils: Critical dependence on Exogenous free fatty acid supply, 757
- Grimwood, S., Moseley, A. M., Carling, R. W., Leeson, P. D., and Foster, A. C. Characterization of the binding of [^3H]L-689,560, an antagonist for the glycine site on the *N*-methyl-D-aspartate receptor, to the rat brain membranes, 923
- Grimwood, S., *see* Foster, A. C., 914
- Gu, J.-L., *see* Yue, T.-L., 281
- Guan, X.-M., Pertoutka, S. J., and Kobilka, B. K. Identification of a single amino acid residue responsible for the binding of a class of β -adrenergic receptor antagonists to 5-hydroxytryptamine $1A$ receptors, 695
- Guay, J., *see* Charleson, S., 873
- Guengerich, F. P., *see* Fleming, C. M., 975
- Guengerich, F. P., *see* Shimada, T., 856
- Guet, T., *see* Randle, J. C. R., 337
- Guidarelli, A., *see* Cantoni, O., 969
- Guidotti, A., *see* Olasmaa, M., 456
- Guillemette, G., *see* Boulay, G., 809
- Gusovsky, F., *see* Soergel, D. G., 487

H

- Hadjilambris, O., *see* Norman, J. A., 53
- Hagiwara, M., *see* Wakusawa, S., 1034
- Hahner, L. D., *see* Leidenheimer, N. J., 1116

- Hajian, G., *see* Domin, B. A., 950
 Han, F.-S., *see* Gao, W.-Y., 223
 Hanley, M. R., *see* D'Santos, C. S., 894
 Hannun, Y. A., *see* Werner, M. H., 382
 Harbon, S., *see* Khac, L. D., 509
 Harman, A. W., Mahar, S. O., Burcham, P. C., and Madsen, B. W.
 Level of cytosolic free calcium during acetaminophen toxicity in
 mouse hepatocytes, 665
 Harris, R. A., *see* Leidenheimer, N. J., 1116
 Hartig, P., *see* Adham, N., 1
 Hartzell, H. C., and Budnitz, D. Differences in effects of forskolin and
 in analog on calcium currents in cardiac myocytes suggest intra-
 and extracellular sites in action, 880
 Helbecque, N., *see* Goossens, J.-F., 104
 Helm, S. W., *see* Henzi, V., 793
 Henichart, J.-P., *see* Bailly, C., 845
 Henichart, J.-P., *see* Goossens, J.-F., 104
 Henzi, V., Reichling, D. B., Helm, S. W., and MacDermott, A. B. L-
 Proline activities glutamate and glycine receptors in cultured rat
 dorsal horn neurons, 793
 Hering, S., *see* Knaus, H.-G., 298
 Herrmann, F., *see* Brach, M. A., 60
 Hickey, R., *see* Bachur, N. R., 993
 Hidaka, H., *see* Wakusawa, S., 1034
 Hide, I., Padgett, W. L., Jacobson, K. A., Daly, J. W. A_{2A} adenosine
 receptors from rat striatum and rat pheochromocytoma PC12 cells:
 Characterization with radioligand binding and by activation of
 adenylate cyclase, 352
 Hijioka, T., Rosenberg, R. I., Lemasters, J. J., and Thurman, R. G.
 Kupffer cells contain voltage-dependent calcium channels, 435
 Hirth, C., *see* Chatrenet, B., 1100
 Hitchcock, M. J. M., *see* Ho, H.-T., 197
 Ho, H.-T., Woods, K. L., Bronson, J. J., De Boeck, H., Martin, J. C.,
 Hitchcock, M. J. M. Intracellular metabolism of the antiherpes
 agent (S)-1-[3-Hydroxy-2-(phosphonylmethoxy)propyl]cytosine,
 197
 Hodge, A. S., Humphrey, D. R., and Rosenberry, T. L. Ambenonium is
 a rapidly reversible noncovalent inhibitor of acetylcholinesterase,
 with one of the highest known affinities, 937
 Hoffman, P. L., *see* Iorio, K. R., 1142
 Holt, B. D., *see* Green, S. A., 889
 Hölting, H.-D., *see* Knaus, H.-G., 298
 Homburger, V., *see* Rouot, B., 273
 Houssier, C., *see* Bailly, C., 845
 Houssin, R., *see* Bailly, C., 845
 Hsu, H. H., *see* Thomas, E. A., 718
 Huang, R.-R. C., *see* Cascieri, M. A., 1096
 Huang, R.-R. C., *see* Cheung, A. H., 1061
 Huang, R.-R. C. *see* Fong, T. M., 24
 Huang, Y.-T., *see* Chao, C. C.-K., 69
 Huber, B. E. Late-stage spermatids are characterized by expression of
 the "liver-specific" asialoglycoprotein receptor, RHL-1, 639
 Huettner, J. E., *see* Swartz, K. J., 1130
 Hughes, M., *see* Crane, M. R., 1073
 Humphrey, D. R., *see* Hodge, A. S., 937
 Hunter, A. L., *see* Thomas, E. A., 718
 Hyland, R., Gescher, A., Thummel, K., Schiller, C., Jheeta, P., Mynett,
 K., Smith, A. W., Mráz, J. Metabolic oxidation and toxification of
 N-methylformamide catalyzed by the cytochrome P450 isoenzyme
 CYP2E1, 259
- I
- Iben, L., *see* Yocca, F. D., 1066
 Im, G. J., *see* Mellors, J. W., 446
 Iorio, K. R., Reinlib, L., Tabakoff, B., and Hoffmann, P. L. Chronic
 exposure of cerebellar granule cells to ethanol results in increased
 N-methyl-D-aspartate receptor function, 1142
 Isenberg, K. E., *see* Zorumski, C. F., 931
 Ishii, K., *see* Warner, T. D., 399
 Israel, M., *see* Romano, C., 785
 Israels, L. G., *see* Yang, W. Z., 625
 Ivins, J. K., *see* Schachter, J. B., 577
- J
- Jacobson, K. A., *see* Hide, I., 352
 Jacobs, R. S., *see* Grace, K. J. S., 631
 Jansing, R. L., Chao, E. S., Kaminsky, L. S. Phase II metabolism of
 warfarin in primary culture of adult rat hepatocytes, 209
 Janssen, P. A. J., *see* Debyser, Z., 203
 Janssen, P. A. J., *see* Leysen, J. E., 494
 Janssen, P.M.F., *see* Leysen, J. E., 494
 Jheeta, P., *see* Hyland, R., 259
 Johnson, D. A., *see* Valenzuela, C. F., 331
 Johnson, P. S., and Michaelis, E. K. Characterization of organophos-
 phate interactions at N-methyl-D-aspartate receptors in brain
 synaptic membranes, 750
 Johnson, R., *see* Bachur, N. R., 993
 Johnston, J. B., *see* Yang, W. Z., 625
 Jones, S. M., *see* Donevan, S. D., 727
 Jones, T. W., *see* Leslie, S. W., 308
 Journot, L., *see* Varrault, A., 993
 Joyeux, H., *see* Pichard, L., 1047
- K
- Kaminsky, L. S., *see* Jansing, R. L., 209
 Kellar, K. J., *see* Flores, C. M., 31
 Kemp, J. A., *see* Foster, A. C., 914
 Kenakin, T. P. Tissue response as a functional discriminator of recep-
 tor heterogeneity: Effects of mixed receptor populations on Schild
 regressions, 699
 Kerr, J. A., *see* Valenzuela, C. F., 331
 Khac, L. D., Mokhtari, A., Renner, M., and Harbon, S. Activation of
 β -adrenergic receptors inhibits Ca²⁺ entry-mediated generation of
 inositol phosphates in the guinea pig myometrium, a cyclic AMP-
 Independent event, 509
 Khan, S., *see* Sastry, J. K., 441
 Kharbanda, S., *see* Brach, M. A., 60
 Kharbanda, S., *see* Datta, R., 64
 Kiedrowski, L., Costa, E., and Wroblewski, J. T. Sodium nitroprusside
 inhibits N-methyl-D-aspartate-evoked calcium influx via a nitric
 oxide- and cGMP-independent mechanism, 779
 Kletzien, R. F., Clarke, S. D., Ulrich, R. G. Enhancement of adipocyte
 differentiation by an insulin-sensitizing agent, 393
 Knaus, H.-G., Striessnig, J., Hering, S., Marrer, S., Schwenner, E.,
 Hölting, H.-D., Glossmann, H. [³⁵S]Sadopine, a novel high affinity,
 high specific activity, L-Type Ca²⁺ channel probe: Characteriza-
 tion of two equipotent diastereomers with opposite allosteric prop-
 erties, 298
 Knecht, K. T., DeGray, J. A., and Mason, R. P. Free radical metabolism
 of halothane *in vivo*: radical adducts detected in bile, 943
 Knoth, K. M., *see* Snyders, D. J., 322
 Ko, W. W. W., *see* Cadario, B. J., 981
 Kobilka, B. K., *see* Guan, X.-M., 695
 Kohlhaas, K. L., *see* Mitchell, J. A., 1163
 Kong, X.-B., Rubin, L., Chen, L.-L., Ciszewska, G., Watanabe, K. A.,
 Tong, W. P., Sirotnak, F. M., Chou, T.-C. Topoisomerase II-
 mediated DNA cleavage activity and irreversibility of cleavable
 complex formation induced by DNA intercalator with alkylating
 capability, 237
 Korman, D. R., *see* Elshourbagy, N. A., 465
 Koroshetz, W. J., *see* Swartz, K. J., 1130
 Koszalka, G. W., *see* Domin, B. A., 950
 Kotzyba-Hibert, F., *see* Chatrenet, B., 1100
 Kozell, L. B., *see* Machida, C. A., 652
 Krause, J., Eva, C., Seeburg, P. H., and Sprengel, R. Neuropeptide Y₁

- subtype pharmacology of a recombinantly expressed neuropeptide receptor, 817
- Kufe, D. E., *see* Datta, R., 64
- Kufe, D. W., *see* Brach, M. A., 60
- Kumar, C. S., *see* Elshourbagy, N. A., 465
- Kumar, D., *see* Norman, J. A., 53
- Kuo, J. F., *see* Chambers, T. C., 1008
- Kurz, J. B., Perkins, J. P. Isoproterenol-initiated β -adrenergic receptor diacytosis in cultured cells, 375

L

- Labarca, C., *see* Charnet, P., 708
- Lambole, B., *see* Randle, J. C. R., 337
- Lau, S. S., *see* Leslie, S. W., 308
- Laurenza, A., Robbins, J. D., Seamon, K. B. Interaction of aminoalkylcarbamates of forskolin with adenylyl cyclase: Synthesis of an iodinated derivative of forskolin with high affinity for adenylyl cyclase, 360
- Law, P. Y., *see* Roerig, S. C., 822
- Lazarowski, E. R., *see* Daniels, A. J., 767
- Lee, J. A., *see* Elshourbagy, N. A., 465
- Lee, Y.-H., *see* Leslie, S. W., 308
- Leeson, P. D., *see* Foster, A. C., 914, 923
- Léger, S., *see* Charleson, S., 873
- Leger, S., *see* Mancini, J. A., 267
- Leidenheimer, N. J., McQuilkin, S. J., Hahner, L. D., Whiting, P., and Harris, R. A. Activation of protein kinase C selectively inhibits the γ -amniobutyric acid_A receptor: Role of desensitization, 1116
- Leith, M. K., *see* Begleiter, A., 677
- Lemasters, J. J., *see* Hijoka, T., 435
- Lemieux, E., *see* Cadario, B. J., 981
- Leonard, K., *see* Berman, H. A., 412
- Lepagnol, J. M., *see* Randle, J. C. R., 337
- Lerma, J., Del Ræio, R. M. Chloride transport blockers prevent N-methyl-D-aspartate receptor-channel complex activation, 217
- Lesko, L. A., *see* Dilger, J. P., 127
- Leslie, S. W., Brown, L. M., Trent, R. D., Lee, Y.-H., Morris, J. L., Jones, T. W., Randall, P. K., Lau, S. S., Monks, T. J. Stimulation of N-methyl-D-aspartate receptor-mediated calcium entry into dissociated neurons by reduced and oxidized glutathione, 308
- Lester, H. A., *see* Charnet, P., 708
- Leysen, J. E., Janssen, P. M. F., Gommeren, W., Wynants, J., Pauwels, P. J., and Janssen, P. A. J. *In vitro* and *in vivo* receptor binding and effects on monoamine turnover in rat brain regions of the novel antipsychotics risperidone and ocapiridone, 494
- Lhermitte, P., *see* Goossens, J.-F., 104
- Liggett, S. B., *see* Green, S. A., 889
- Lin-Chao, S., *see* Chao, C. C.-K., 69
- Loew, G. H., *see* Cometia-Morini, C., 185
- Loh, H. H., *see* Roerig, S. C., 822
- Lohez, M., *see* Goossens, J.-F., 104
- Loscig, J., *see* Appell, K. C., 772
- Lucas, E., *see* Soleilhac, J. M., 609
- Lummis, S. C. R., Martin, I. L. Solubilization, purification, and functional reconstruction of 5-hydroxytryptamine₂ receptors from N1E-115 neuroblastoma cells, 18
- Luong, T., *see* Thomas, E. A., 718
- Luong, T.-T., *see* Boulay, G., 809

M

- Ma, C. M. *see* Chao, C. C.-K., 69
- MacDermott, A. B., *see* Henzi, V., 793
- Macdonald, R. L., *see* Rock, D. M., 83
- Machida, C. A., Searles, R. P., Nipper, V., Brown, J. A., Kozell, L. B., and Neve, K. A. Molecular cloning and expression of the rhesus macaque D1 dopamine receptor gene, 652
- Madden, B. J., *see* Otterness, D. M., 856

- Madsen, B. W., *see* Harman, A. W., 665
- Maguire, P. A., *see* Cometia-Morini, C., 185
- Mahar, S. O., *see* Harman, A. W., 665
- Mahony, W. B., *see* Domin, B. A., 950
- Makowiec, R. L., *see* Cha, J.-H. J., 832
- Malkas, L., *see* Bachur, N. R., 993
- Mancini, J. A., Prasit, P., Coppolino, M. G., Charleson, P., Leger, S., Evans, J. F., Gillard, J. W., Vickers, P. J. 5-Lipoxygenase-activating protein is the target of a novel hybrid of two classes of leukotriene biosynthesis inhibitors, 267
- Mancini, J. A., *see* Charleson, S., 873
- Maren, T. H. Direct measurements of the rate constants of sulfonamides with carbonic anhydrase, 419
- Marrer, S., *see* Knaus, H.-G., 298
- Marshall, G. R., *see* Foster, A. C., 914
- Marshall, G. R., *see* Romano, C., 785
- Martin, I. L., *see* Lummis, S. C. R., 18
- Martin, J., *see* Ho, H.-T., 197
- Mash, D. C., *see* Flynn, D. D., 736
- Mason, R. P., *see* Knecht, K. T., 934
- Mather, R. J., *see* Simmons, M. A., 527
- Matsumoto, T., *see* Mitchell, J. A., 1163
- Matthews, J. E., *see* Daniels, A. J., 767
- Maurel, P., *see* Pichard, L., 1047
- Mauz, A. B. M., *see* Wienen, W., 1081
- McCormick, D. J., *see* Otterness, D. M., 856
- McQuilkin, S. J., *see* Leidenheimer, N. J., 1116
- Medina, M., *see* Grace, K. J. S., 631
- Meller, E., *see* Yocca, F. D., 1066
- Mellors, J. W., Dutschman, G. E., Im, G.-J., Tramontano, E., Winkler, S. R., and Cheng, Y.-C. *In vitro* selection and molecular characterization of human immunodeficiency virus-1 resistant to non-nucleoside inhibitors of reverse transcriptase, 446
- Michaelis, E. K., *see* Johnson, P. S., 750
- Michel, J. B., *see* Soleilhac, J. M., 609
- Miledi, R., *see* Woodward, R. M., 89, 1107
- Miller, R. J., *see* Brorson, J. R., 603
- Minneman, K. P., *see* Atkinson, B. N., 688
- Mirabelli, C. K., *see* Bennett, C. F., 1023
- Mitchell, B. S., *see* Dayton, J. S., 671
- Mitchell, J. A., Kohlhaas, K. L., Matsumoto, T., Pollock, J. S., Förstermann, U., Warner, T. D., Schmidt, H. H. H. W., and Murad, F. Induction of NADPH-dependent diaphorase and nitric oxide synthase activity in aortic smooth muscle and cultured macrophages, 1163
- Mitchell, J. A., *see* Warner, T. D., 399
- Miyamoto, K.-I., *see* Wakusawa, S., 1034
- Moisey, D. M., *see* Preston Mason, R., 315
- Mokhtari, A., *see* Khac, L. D., 509
- Molinob, P. B., *see* Romano, C., 785
- Monks, T. J., *see* Leslie, S. W., 308
- Montgomery, J. A., *see* Parker, W. B., 245
- Moreau, C., *see* Randle, J. C. R., 337
- Morris, J. L., *see* Leslie, S. W., 308
- Moseley, A. M., *see* Foster, A. C., 923
- Mowat, M. R. A., *see* Yang, W. Z., 625
- Mráz, J., *see* Hyland, R., 259
- Mulle, C., *see* Chatrenet, B., 1100
- Munson, P. J., *see* Costa, T., 549
- Murad, F., *see* Mitchell, J. A., 1163
- Murad, F., *see* Schmidt, H. H. W., 615
- Murad, F., *see* Warner, T. D., 399
- Murray, T. F., *see* Franklin, P. H., 134
- Murrin, R. J. A., and Boarder, M. R. Neuronal "nucleotide" receptor linked to phospholipase C and phospholipase D? Stimulation of PC12 cells by ATP analogues and UTP, 561
- Mussap, C. J., *see* Geraghty, D. P., 147
- Mynett, K., *see* Hyland, R., 259

N

- Nakamura, S., *see* Wakusawa, S., 1034
 Nakane, M., *see* Schmidt, H. H. W., 615
 Nantel, F., *see* Suzuki, T., 542
 Nargeot, J., *see* Ouadid, H., 346
 Nehete, P. N., *see* Sastry, J. K., 441
 Neve, K. A., *see* Machida, C. A., 652
 Nguyen, C. T., *see* Suzuki, T., 542
 Nicoletti, F., *see* Condorelli, D. F., 660
 Nipper, V., *see* Machida, C. A., 652
 Nishio, S., *see* Overby, L. H., 1039
 Norman, J. A., Hadjilambris, O., Baska, R., Sharp, D. Y., Kumar, R.
 Stable expression, secretion, and characterization of active human
 renin in mammalian cells, 53
 Nowak, B. J., *see* Sastry, J. K., 441
 Nowak, L. M., *see* Wright, J. M., 900
 Nunn, D. L., Taylor, C. W. Luminal Ca^{2+} increases the sensitivity of
 Ca^{2+} stores to inositol 1,4,5-trisphosphate, 115
 Nuthalaganti, P., *see* Elshourbagy, N. A., 465

O

- O'Brian, C. A., *see* Ward, N. E., 387
 Ogino, Y., *see* Costa, T., 549
 O'Hanley, P. D., *see* Crane, M. R., 1073
 O'Huigin, C., *see* Bailly, C., 845
 Olasmaa, M., Guidotti, A., and Costa, E. Vasoactive intestinal polypep-
 tide facilitates tyrosine hydroxylase induction by cholinergic ago-
 nists in bovine adrenal chromaffin cells, 456
 Onaran, H. O., *see* Costa, T., 549
 Otterness, D. M., Wieben, E. D., Wood, T. C., Watson, R. W. G.,
 Madden, B. J., McCormick, D. J., and Weinshilboum, R. M.
 Human liver dehydroepiandrosterone sulfotransferase: Molecular
 cloning and expression of cDNA, 865
 Ouadid, H., Seguin, J., Dumuis, A., Bockaert, J., Nargeot, J. Serotonin
 increases calcium current in human atrial myocytes via the newly
 described 5-hydroxytryptamine₄ receptors, 346
 Overby, L. H., Nishio, S., Weir, A., Carver, G. T., Plopper, C. G., and
 Philpot, R. M. Distribution of cytochrome P450 1A1 and NADPH-
 cytochrome P450 reductase in lungs of rabbits treated with 2,3,7,
 8-tetrachlorodibenzo-*p*-dioxin: Ultrastructural immunolocaliza-
 tion and *in situ* hybridization, 1039

P

- Pabreza, L. A., *see* Flores, C. M., 31
 Padgett, W. L., *see* Hide, I., 352
 Painter, G. R., *see* Wright, L. L., 957
 Pak, R. C. K., *see* Cadario, B. J., 981
 Panten, U., *see* Schwanstecher, D., 480
 Parker, W. B., Shaddix, S. C., Allan, P. W., Arnett, G., Rose, L. M.,
 Shannon, W. M., Fulmer Shealy, Y., Montgomery, J. A., Secrist,
 J. A., III, Bennett, L. L., Jr. Incorporation of the carbocyclic analog
 of 2'-deoxyguanosine into the DNA of herpes simplex virus and of
 HEp-2 cells infected with herpes simplex virus, 245
 Pasquali, D., Rani, C. S. S., Deery, W. J. Carbachol-induced decrease
 in thyroid cell adenylyl cyclase activity is independent of calcium
 and phosphodiesterase activation, 163
 Pauwels, P. J., *see* Leysen, J. E., 494
 Pauwels, R., *see* Debyser, Z., 203, 963
 Penney, J. B., *see* Cha, J.-H. J., 832
 Pepin, M.-C., Govindan, M. V., and Barden, N. Increased glucocorticoid
 receptor gene promoter activity after antidepressant treatment,
 1016
 Pereira, E. F. R., *see* Alkondon, M., 802
 Perkins, J. P., *see* Kurz, J. B., 375
 Peroutka, S. J., *see* Guan, X.-M., 695
 Philpot, R. M., *see* Overby, L. H., 1039
 Pichard, L., Fabre, I., Daujat, M., Domergue, J., Joyeux, H., and Maurel,
 P. Effect of corticosteroids on the expression of cytochromes P450

and on cyclosporin A oxidase activity in primary cultures of human
 hepatocytes, 1047

- Pittman, R. N., *see* Schachter, J. B., 577
 Plopper, C. G., *see* Overby, L. H., 1039
 Plunkett, W., *see* Sastry, J. K., 441
 Polenzani, L., *see* Woodward, R. M., 89, 1107
 Pollock, J., *see* Mitchell, J. A., 1163
 Pommery, J., *see* Goossens, J.-F., 104
 Pommery, N., *see* Goossens, J.-F., 104
 Porter, D. J. T., *see* Domin, B. A., 950
 Powell, P., *see* Quist, E., 177
 Powers, D. A., *see* Yue, T.-L., 281
 Poyner, D. R., *see* D'Santos, C. S., 894
 Prasit, P., *see* Charleson, S., 873
 Prasit, P., *see* Mancini, J. A., 267
 Preston Mason, R., Moisey, D. M., Shajenko, L. Cholesterol alters the
 binding of Ca^{2+} channel blockers to the membrane lipid bilayer,
 315
 Priestley, T., *see* Foster, A. C., 914
 Punzi, J. S., Duax, W. L., Strong, P., Griffin, J. F., Flocco, M. M.,
 Zacharias, D. E., Carrell, H. L., Tew, K. D., and Glusker, J. P.
 Molecular conformation of estramustine and two analogues, 569

Q

- Qu, W., Savier, E., and Thurman, R. G. Stimulation of monooxygena-
 tion and conjugation after liver transplantation in the rat: Involvement
 of Kupffer cells, 1149
 Quist, E., Powell, P., Vasan, R. Guanylnucleotide specificity for mus-
 carinic receptor inhibitory coupling to cardiac adenylyl cyclase,
 177
 Quist, E. Regulation of GDP and GTP binding in cardiac sarcolemma
 by muscarinic receptor agonists, 168

R

- Rampe, D., and Dage, R. C. Functional interactions between two Ca^{2+} -
 channel activators, (S)-Bay K 8644 and FPL 64176, in smooth
 muscle, 599
 Randall, P. K., *see* Leslie, S. W., 308
 Randle, J. C. R., Guet, T., Bobichon, C., Moreau, C., Curutchet, P.,
 Lambolez, B., De Carvalho, L. P., Cordi, A., Lepagnol, J. M.
 Quinoxaline derivatives: Structure-activity relationships and phys-
 iological implications of inhibitors of *N*-Methyl-D-aspartate and
 Non-*N*-methyl-D-aspartate receptor-mediated currents and syn-
 aptic potentials, 337
 Rani, C. S. S., *see* Pasquali, D., 163
 Rees, A. H., *see* Swartz, K. J., 1130
 Reichling, D. B., *see* Henzi, V., 793
 Reider, N., *see* Zernig, G., 45
 Reinlib, L., *see* Iorio, K. R., 1142
 Reisine, T., *see* Tallent, M., 452
 Renner, M., *see* Khac, L. D., 509
 Reynolds, I. J. 1, 5-(Diethylamino)piperidine, a novel spermidine ana-
 logue that more specifically activates the *N*-methyl-D-aspartate
 receptor-associated polyamine site, 989
 Rivalle, C., *see* Bailly, C., 845
 Robbins, J. D., *see* Laurenza, A., 360
 Roberds, S. L., *see* Snyders, D. J., 322
 Roberts, E. S., Vaz, A. D. N., Coon, M. J. Role of isozymes of rabbit
 microsomal cytochrome P-450 in the metabolism of retinoic acid,
 retinol, and retinal, 427
 Robotham, E., *see* Begleiter, A., 677
 Rock, D. M., Macdonald, R. L. The polyamine spermine has multiple
 actions on *N*-methyl-D-aspartate receptor single-channel currents
 in cultured cortical neurons, 83
 Rodbard, D., *see* Costa, T., 549
 Roerig, S. C., Loh, H. H., and Law, P. Y. Identification of three separate
 guanine nucleotide-binding proteins that interact with the δ -opioid
 receptor in NG108-15 neuroblastoma $\times$ glioma hybrid cells, 822

- Rogawski, M. A., *see* Donevan, S. D., 727
 Rogers, S. W., *see* Flores, C. M., 31
 Romanienko, P., *see* Adham, N., 1
 Romano, C., Williams, K., DePriest, S., Seshadri, R., Marshall, G. R., Israel, M., and Molinob, P. B. Effects of mono-, di-, and triamines on the *N*-methyl-D-aspartate receptor complex: A model of the polyamine recognition site, 785
 Roques, B. P., *see* Durieux, C., 1089
 Roques, B. P., *see* Soleilhac, J. M., 609
 Rose, L. M., *see* Parker, W. B., 245
 Rosenberg, R. I., *see* Hijoka, T., 435
 Rosenberry, T. L., *see* Hodge, A. S., 937
 Rouot, B., Charpentier, N., Chabbert, C., Carrette, J., Zumbihl, R., Bockaert, J., Homburger, V. Specific antibodies against G_o isoforms reveal the early expression of the $G_{o2\alpha}$ subunit and appearance of $G_{o1\alpha}$ during neuronal differentiation, 273
 Rubin, L., *see* Kong, X.-B., 237
 Ruiz-Gayo, M., *see* Durieux, C., 1089
- S
- Saavedra, J. M., *see* Tsutsumi, K., 290
 Sadowski, S., *see* Cascieri, M. A., 1096
 Salgado, V. L. Slow voltage-dependent block of sodium channels in crayfish nerve by dihydropyrazole insecticides, 120
 Sarau, H. M., *see* Yue, T.-L., 281
 Sastry, J. K., Nehete, P. N., Khan, S., Nowak, B.J., Plunkett, W., Arlinghaus, R. B., and Farquhar, D. Membrane-permeable dideoxyuridine 5'-monophosphate analogue inhibits human immunodeficiency virus infection, 441
 Savier, E., *see* Qu, W., 1149
 Schachter, J. B., and Wolfe, B. B. Cyclic AMP differentiates two separate but interacting pathways of phosphoinositide hydrolysis in the DDT₁-MF₂ smooth muscle cell line, 587
 Schachter, J. B., Ivins, J. K., Pittman, R. N., and Wolfe, B. B. Competitive regulation of phospholipase C responses by cAMP and calcium, 577
 Schiller, C., *see* Hyland, R., 259
 Schmidt, H. H. W., *see* Mitchell, J. A., 1163
 Schmidt, H. H. W., Warner, T. D., Nakane, M., Förstermann, U., and Murad, F. Regulation and subcellular location of nitrogen oxide synthases in RAW264.7 macrophages, 615
 Schwanstecher, C., Dickel, C., and Panten, U. Cytosolic nucleotides enhance the tolbutamide sensitivity of the ATP-dependent K⁺ channel in mouse pancreatic B cells by their combined actions at inhibitory and stimulatory receptors, 480
 Schwartz, R. D., *see* Edgar, P. P., 1124
 Schwenner, E., *see* Knaus, H.-G., 298
 Seamon, K. B., *see* Laurenza, A., 360
 Searles, R. P., *see* Machida, C. A., 652
 Secrist, J. A. III, *see* Parker, W. B., 245
 Seeburg, P. H., *see* Krause, J., 817
 Seeger, W., *see* Grimminger, F., 757
 Seguin, J., *see* Ouadid, H., 346
 Servant, G., *see* Boulay, G., 809
 Seshadri, R., *see* Romano, C., 785
 Sestili, P., *see* Cantoni, O., 969
 Shaddix, S. C., *see* Parker, W. B., 245
 Shajenko, L., *see* Preston Mason, R., 315
 Shannon, W. M., *see* Parker, W. B., 245
 Sharp, D. Y., *see* Norman, J. A., 53
 Shearer, B. G., *see* Sullivan, J. P., 38
 Shimada, S., Cutting, G., and Uhl, G. R. γ -Aminobutyric acid or C receptor? γ -Aminobutyric acid receptor RNA induces bicuculline-, barbiturate-, and benzodiazepine-insensitive γ -aminobutyric acid responses in *Xenopus* oocytes, 683
 Shimada, T., Yun, C.-H., Yamazaki, H., Gautier, J.-C., Beaune, P. H., and Guengerich, F. P. Characterization of human lung microsomal cytochrome P-450 1A1 and its role in the oxidation of chemical carcinogens, 856
 Shoemaker, J. E. E., *see* Bennett, C. F., 1023
 Shon, D. H., *see* Yun, Y.-P., 474
 Simmons, M. A., and Mather, R. J. Intracellular guanosine-5'-O-(2-thiodiphosphate) alters the dynamics of receptor-mediated responses in bullfrog sympathetic neurons, 527
 Singh, S., *see* Appell, K. C., 772
 Sirotnak, M., *see* Kong, X.-B., 237
 Smith, A. W., *see* Hyland, R., 259
 Smith, J. D., *see* Foster, A. C., 914
 Snyders, D. J., Knoth, K. M., Roberds, S. L., Tamkun, M. M. Time-, voltage-, and state-dependent block by quinidine of a cloned human cardiac potassium channel, 322
 Sobol, M. M., Amiet, R. G., Green, M. D. *In vitro* evidence for direct complexation of ADR-529/ICRF-187 [(+)-1,2-bis-(3,5-dioxopiperazin-1-yl)propane] onto an existing ferric-anthracycline complex, 8
 Soergel, D. G., Yasumoto, T., Daly, J. W., and Gusovsky, F. Maitotoxin effects are blocked by SK&F 96365, an inhibitor of receptor-mediated calcium entry, 487
 Soleilhac, J. M., Lucas, E., Beaumont, A., Turcaud, S., Michel, J. B., Ficheux, D., Fournié-Zaluski, M. C., and Roques, B. P. A 94-kDa protein, identified as neutral endopeptidase-24.11, can inactivate atrial natriuretic peptide in the vascular endothelium, 609
 Sommadossi, J.-P., *see* Weidner, D. A., 252
 Song, B., *see* Yun, Y.-P., 474
 Sortino, M. A., *see* Condorelli, D. F., 660
 Sprengel, R., *see* Krause, J., 817
 Stadel, J. M., *see* Yue, T.-L., 281
 Stoltefuss, J., *see* Zheng, W., 535
 Storm, C., *see* Gao, W. Y., 223
 Strader, C. D., *see* Barber, D. L., 1056
 Strader, C. D., *see* Cascieri, M. A., 1096
 Strader, C. D., *see* Cheung, A. H., 1061
 Strader, C. D. *see* Fong, T. M., 24
 Striessnig, J., *see* Knaus, H.-G., 298
 Strong, P., *see* Punzi, J. S., 569
 Sullivan, J. P., Connor, J. R., Shearer, B. G., Burch, R. M. 2,6-Diamino-*N*-[(1-(1-oxotridecyl)-2-piperidinyl)methyl]hexanamide (NPC 15437): A novel inhibitor of protein kinase C interacting at the regulatory domain, 38
 Sutiphong, J. A., *see* Elshourbagy, N. A., 465
 Suzuki, T., Nguyen, C. T., Nantel, F., Bonin, H., Valiquette, M., Frielle, T., and Bouvier, M. Distinct regulation of β_1 - and β_2 -adrenergic receptors in Chinese hamster fibroblasts, 542
 Swartz, K. J., Koroshetz, W. J., Rees, A. H., and Huettner, H. E. Competitive antagonism of glutamate receptor channels by substituted benzazepines in cultured cortical neurons, 1130
 Swillens, S. Dynamic control of inositol 1,4,5-trisphosphate-induced Ca^{2+} release: A theoretical explanation for the quantal release of Ca^{2+} , 110
 Sylvester, D. R., *see* Elshourbagy, N. A., 465
- T
- Tabakoff, B., *see* Iorio, K. R., 1142
 Tajima, K., *see* Wakusawa, S., 1034
 Tallent, M., and Reisine, T. G_{o1} selectively couples somatostatin receptors to adenylyl in pituitary-derived AtT-20 cells, 452
 Tamkun, M. M., *see* Snyders, D. J., 322
 Taylor, C. W., *see* Nunn, D. L., 115
 Tew, K. D., *see* Punzi, J. S., 569
 Thio, L. L., *see* Zorumski, C. F., 931
 Thomas, E. A., Hsu, H. H., Griffin, M. T., Hunter, A. L., Luong, T., and Ehlert, F. J. Conversion of *N*-(2-chloroethyl)-4-piperidinyl diphenylacetate (4-DAMP mustard) to an aziridinium ion and its interaction with Muscarinic receptors in various tissues, 718
 Thomas, P. E., *see* Wrighton, S. A., 76

- Thompson, C. B., *see* Dayton, J. S., 671
 Thummel, K., *see* Hyland, R., 259
 Thurman, R. G., *see* Hijoka, T., 435
 Thurman, R. G., *see* Qu, W., 1149
 Tomczuk, B. E., *see* Appell, K. C., 772
 Tong, W. P., *see* Kong, X.-B., 237
 Townsend, A. J., Tu, C.-P. D., Cowan, K. H. Expression of human μ or α class glutathione S-transferases in stably transfected human MCF-7 breast cancer cells: Effect on cellular sensitivity cytotoxic agents, 230
 Tramontano, E., *see* Mellors, J. W., 446
 Trent, R. D., *see* Leslie, S. W., 308
 Triggler, D. J. *see* Zheng, W., 535
 Tsutsumi, K., Saavedra, J. M. Heterogeneity of angiotensin II AT₂ receptors in the rat brain, 290
 Tu, C.-P. D., *see* Townsend, A. J., 230
 Turcaud, S., *see* Soleilhac, J. M., 609
 Turka, L. A., *see* Dayton, J. S., 671
- U
- Uhl, G. R., *see* Shimada, S., 683
 Ulrich, R. G., *see* Kletzien, R. F., 393
- V
- Vaishnav, A. A., *see* Flynn, D. D., 736
 Valenzuela, C. F., Kerr, J. A., Duvvuri, P., Johnson, D. A. Modulation of phencyclidine-sensitive ethidium binding to the *Torpedo* acetylcholine receptor: Interaction of noncompetitive inhibitors with carbamylcholine and cobra α -toxin, 331
 Valiquette, M., *see* Suzuki, T., 542
 Van Berkel, T. J. C., *see* Bijsterbosch, M. K., 404
 Vandenbranden, M., *see* Wrighton, S. A., 76
 Van Meel, J. C. A., *see* Wienen, W., 1081
 Varrault, A., Journot, L., Audigier, Y., and Bockaert, J. Transfection of human 5-hydroxytryptamine_{1A} receptors in NIH-3T₃ fibroblasts: effects of increasing receptor density on coupling of 5-hydroxytryptamine_{1A} receptors to adenylyl cyclase, 999
 Vasan, R., *see* Quist, E., 177
 Vaz, A. D. N., *see* Roberts, E. S., 427
 Veech, R. L., *see* Yun, Y.-P., 474
 Vickers, P. H., *see* Mancini, J. A., 267
 Vickers, P. J., *see* Charleson, S., 873
 Viveros, O. H., *see* Daniels, A. J., 767
 Vrana, K. E., *see* Vrana, S. L., 839
 Vrana, S. L., Azzaro, A. J., and Vrana, K. E. Chronic selegiline administration transiently decreases tyrosine hydroxylase activity and mRNA in the rat nigrostriatal pathway, 839
- W
- Wakusawa, S., Nakamura, S., Tajima, K., Miyamoto, K.-I., Hagiwara, M., and Hidaka, H. Overcoming of vinblastine resistance by isoquinolinesulfonamide compounds in adriamycin-resistant leukemia cells, 1034
 Waldman, S. A., *see* Crane, M. R., 1073
 Wang, H.-Y., *see* Yue, T.-L., 281
 Ward, N. E., O'Brian, C. A. Kinetic analysis of protein kinase C inhibition by staurosporine: Evidence that inhibition entails inhibitor binding at a conserved region of catalytic domain but not competition with substrates, 387
 Waring, M. J., *see* Bailly, C., 845
 Warner, T. D., Mitchell, J. A., D'Orleans-Juste, P., Ishii, K., Förstermann, U., Murad, F. Characterization of endothelin-converting enzyme from endothelial cells and rat brain: Detection of the formation of biologically active endothelin-1 by rapid bioassay, 399
 Warner, T. D., *see* Mitchell, J. A., 1163
 Warner, T. D., *see* Schmidt, H. H. W., 615
 Watanabe, K. A., *see* Kong, X.-B., 237
 Watson, R. W. G., *see* Otterness, D. M., 856
 Weidner, D. A., Bridges, E. G., Cretton, E. M., Sommadossi, J.-P. Comparative effects of 3'-azido-3'-deoxythymidine and its metabolic 3'-amino-3'-deoxythymidine on hemoglobin synthesis in K-562 human leukemia cells, 252
 Weinshank, R. L., *see* Adham, N., 1
 Weinshilboum, R. M., *see* Otterness, D. M., 856
 Weir, A., *see* Overby, L. H., 1039
 Werner, M. H., Bielawska, A. E., Hannun, Y. A., Quantitative analysis of diacylglycerol second messengers in human platelets: Correlation with aggregation and secretion, 382
 Wess, J., Gdula, D., Brann, M. R. Structural basis of subtype selectivity of muscarinic antagonists: A study with chimeric m2/m5 muscarinic receptors, 369
 White, M. M., *see* Aylwin, M. L., 908
 Whiting, P., *see* Leidenheimer, N. J., 1116
 Wieben, E. D., *see* Otterness, D. M., 856
 Wienen, W., Mauz, A. B. M., Van Meel, J. C. A., and Entzeroth, M. Different types of receptor interaction of peptide and nonpeptide angiotensin II antagonists revealed by receptor binding and functional studies, 1081
 Wilkinson, G. R., *see* Fleming, C. M., 975
 Williams, K., *see* Romano, C., 785
 Wilson, L., *see* Grace, K. J. S., 631
 Winkler, S. R., *see* Mellors, J. W., 446
 Wolfe, B. B., *see* Flores, C. M., 31
 Wolfe, B. B., *see* Schachter, J. B., 577, 587
 Wonnacott, S., *see* Alkondon, M., 802
 Wood, T. C., *see* Otterness, D. M., 856
 Woods, K. L., *see* Ho, H.-T., 197
 Woodward, R. M., Polenzani, L., and Miledi, R. Effects of hexachlorocyclohexanes on γ -aminobutyric acid receptors expressed in *Xenopus* oocytes by RNA from mammalian brain and retina, 18
 Woodward, R. M., Polenzani, L., Miledi, R. Effects of steroid on γ -aminobutyric acid receptors expressed in *Xenopus* oocytes by poly(A)+ RNA from mammalian brain and retina, 89
 Wright, J. M., and Nowak, L. M. Effects of low doses of bicuculline and N-Methyl-D-aspartate single-channel kinetics are not evident in whole-cell currents, 900
 Wright, L. L., and Painter, G. R. Role of desolvation energy in the nonfacilitated membrane permeability of dideoxyribose analogs of thymidine, 957
 Wrighton, S. A., Vandenbranden, M., Becker, G. W., Black, S. D., Thomas, P. E. Two monoclonal antibodies recognizing different epitopes on rat cytochrome IIB1 react with human IIE1, 76
 Wroblewski, J. T., *see* Kiedrowski, L., 779
 Wu, Y., *see* Bachur, N. R., 993
 Wynants, J., *see* Leysen, J. E., 494
- Y
- Yamazaki, H. *see* Shimada, T., 856
 Yang, W. Z., Begleiter, A., Johnston, J. B., Israels, L. G., and Mowat, M. R. A. Role of glutathione and glutathione S-transferase in chlorambucil resistance, 625
 Yasumoto, T., *see* Soergel, D. G., 487
 Yocca, F. D., Iben, L., and Meller, E. Lack of apparent receptor reserve at postsynaptic 5-hydroxytryptamine_{1A} receptors negatively coupled to adenylyl cyclase activity in rat hippocampal membranes, 1066
 Young, A. V., *see* Cha, J.-H. J., 832
 Yu, F., *see* Bachur, N. R., 993
 Yu, H., *see* Fong, T. M., 24
 Yue, T.-L., Stadel, M., Sarau, H. M., Friedman, E., Gu, J.-L., Powers, D. A., Gleason, M. M., Feuerstein, G., Wang, H.-Y. Platelet-activating factor stimulates phosphoinositide turnover in neurohybrid NCB-20 cells; involvement of pertussis toxin-sensitive guanine nucleotide-binding proteins and inhibition by protein kinase C, 281

Yun, C.-H., *see* Shimada, T., 856

Yun, Y.-P., Casazza, J. P., Shon, D. H., Veech, R. L., and Song, B. J. Pretranslational activation of cytochrome P450IIE during ketosis induced by a high fat diet, 474

Z

Zacharias, D. E., *see* Punzi, J. S., 569

Zernig, G., Reider, N. Ion dependence of the partially purified mitochondrial dihydropyridine Ca²⁺ antagonist receptor, 45

Zhang, Y., *see* Garritsen, A., 743

Zheng, B., *see* Chambers, T. C., 1008

Zheng, W., Stoltefuss, J., Goldmann, S., and Triggle, D. J. Pharmacologic and radioligand binding studies of 1,4-Dihydropyridines in rat cardiac and vascular preparations: Stereoselectivity and voltage dependence of antagonist and activator interactions, 535

Zimmerman, T. P., *see* Domin, B. A., 950

Zorumski, C. F., Thio, L. L., Isenberg, K. E., and Clifford, D. B. Nicotinic acetylcholine currents in cultured postnatal rat hippocampal neurons, 931

Zumbihl, R., *see* Rouot, B., 273

SUBJECT INDEX FOR VOLUME 41

A

- Acetaminophen, toxicity in hepatocytes, level, cytosolic free calcium (mouse), 665
- Acetylcholine, binding site, photoactivable agonist, nicotinic acetylcholine receptor, 1100
- Acetylcholinesterase
interaction of tetrahydroaminoacridine (*Torpedo*), 412
noncovalent inhibitor ambenonium, one of highest known affinities (human), 937
- Adenosine triphosphate
analogues and UTP, neuronal "nucleotide" receptor, phospholipase C and D, 561
-dependent K⁺ channel in pancreatic B cells, tolbutamide sensitivity, cytosolic nucleosides (mouse), 480
regulation of signal transduction, purinergic receptor, NCB-20 cells, 743
- Adenylate cyclase
adenosine A_{2A} receptors, striatum and PC12 cells (rat), 352
cardiac, guanylnucleotide specificity, muscarinic receptor inhibitory coupling (dog), 177
stimulation by amylin, CHO-K1 cells, 894
- Adenylyl cyclase
activity in hippocampal membranes, lack of apparent receptor reserve, 5-HT_{1A} (rat), 1066
beta adrenoceptors, subtype-selective coupling to G_s (bullfrog), 889
interaction of aminoalkylcarbamates (bovine), 360
neuropeptide Y₁ subtype pharmacology, recombinantly expressed neuropeptide receptor, 817
SRIF receptor coupling, pituitary-derived AtT-20 cells, 452
transfection of human 5-HT_{1A} receptors, NIH-3T3 cells, 999
uncoupled β -adrenergic receptors, mutant constructs, functional activation of Na-H exchange, 1056
- Adipocytes, enhancement of differentiation, insulin-sensitizing agent, 393
- Adrenal chromaffin cells, vasoactive intestinal polypeptide, tyrosine hydroxylase induction, cholinergic agonists (bovine), 456
- Adrenal gland, immunological characterization, dehydroepiandrosterone sulfotransferase (human), 645
- Adrenal glomerulosa, modulation of angiotensin II binding affinity, allosteric interaction, polyvinyl sulfate, 809
- Adrenoceptors
alpha, isoproterenol-initiated diacytosis, cultured cells (human), 375
beta
activation of Na-H exchange, mutant constructs, 1056
binding to 5-HT_{1A} receptors, single amino acid residue, 695
hydrophobic amino acids, activation of G_s and third intracellular loop, 1061
inhibition of Ca²⁺ entry-mediated generation, inositol phosphates (guinea pig), 509
subtype-selective coupling to G_s (bullfrog), 889
beta versus *alpha*-2, loss of response to norepinephrine, primary glial cultures (rat), 688
- Adriamycin
ADR-529 Fe³⁺-anthracycline complex, direct complexation, 8
multidrug-resistant colon cancer cell line, glutathione S-transferase overexpression, thiol pools (human), 69
-resistant leukemia cells, overcoming vinblastine resistance, isoquinolinesulfonamide compounds, 1034
- Alkylformamides, *N*-methylformamide, metabolic oxidation and toxification, CYP2E1 (mouse), 259
- Ambenonium, noncovalent inhibitor of acetylcholinesterase, one of highest known affinities (human), 937

Amino acid

- determination of residues, substance P selectivity and specificity, neurokinin receptors (rat), 1096
- hydrophobic, third intracellular loop, β -adrenergic receptor in activation of G_s, 1061
- selectivity of transmitters, NMDA and amino-3-hydroxy-5-methyl-4-isoxazolepropionate receptors (rat), 520
- Aminoalkylcarbamates, forskolin, interaction with adenylyl cyclase (bovine), 360
- γ -Aminobutyric acid, A or C receptors, *Xenopus* oocytes, 683
- (*RS*)- α -Amino-3-hydroxy-5-methylisoxazole-4-propionic acid, receptors in brain, multiple states, quantitative autoradiography (rat), 832
- Amlodipine, alteration of binding to membrane lipid bilayer, cholesterol (rabbit), 315
- Amylin, stimulation of adenylate cyclase, CHO-K1 cells, 894
- Anesthetics, isoflurane, acetylcholine receptor channels, 127
- Angiotensin II
modulation of binding affinity, allosteric interaction, polyvinyl sulfate, 809
modulation of binding by allosteric interaction, polyvinyl sulfate, bovine adrenal glomerulosa, 809
peptide and nonpeptide antagonists, receptor interaction, 1081
- Antagonists, tissue response as a functional discriminator, receptor heterogeneity, Schild regressions, 699
- Anthracycline
ADR-529 Fe³⁺ complex, direct complexation, 8
anticancer agents, helicase inhibition, 993
- Antidepressants, increased glucocorticoid receptor gene promoter activity, 1016
- Antipsychotics, risperidone and ocapiridone, receptor binding, monoamine turnover (rat), 494
- Antisense technology, phosphorothioate oligonucleotides, inhibitors, DNA polymerases and RNase H (human), 223
- 1- β -D-Arabinofuranosylcytosine
transcriptional and posttranscriptional regulation, H1 histone gene expression, 64
transcription factor κ B, human myeloid leukemia cells, 60
- Arcaine, block of *N*-methyl-D-aspartate receptor responses, open channel mechanism, hippocampal neurons (rat), 727
- Asialoglycoprotein, receptor RHL-1, late-stage spermatids (rat), 639
- Atrial natriuretic peptide, inactivation, neutral endopeptidase-24.11, vascular endothelium (rat, rabbit, human), 609
- AtT-20 cells, pituitary-derived, SRIF receptor/adenylyl cyclase coupling, 452
- Autoradiography, (*RS*)- α -amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors, multiple states, brain (rat), 832
- Azathioprine, compared to mizoribine, T cell proliferation, purine ribonucleotide metabolism (human), 671
- 3'-Azido-3'-deoxythymidine, metabolite and, hemoglobin synthesis, K-562 cells, 252
- 5'-Azido-5'-deoxythymidine, membrane permeation characteristics (human), 950
- Aziridinium ion, conversion of *N*-(2-chloroethyl)-4-piperidinyl diphenylacetate, interaction with muscarinic receptors, 718

B

- Barbiturate, γ -aminobutyric acid A or C receptor, *Xenopus* oocytes, 683
- (*S*)-Bay K 8644, FPL 64176 and, functional interactions, smooth muscle (rat), 599

- B cells, pancreatic, cytosolic nucleosides and tolbutamide sensitivity, ATP-dependent K^+ channel (mouse), 480
- Benzazepines, substituted, competitive antagonism of glutamate receptor channels, cortical neurons, 1130
- Benzodiazepine, γ -aminobutyric acid A or C receptor, *Xenopus* oocytes, 683
- Bicuculline
 γ -aminobutyric acid A or C receptor, *Xenopus* oocytes, 683
 low doses, NMDA single-channel kinetics, whole-cell currents (mouse), 900
- Bile, detection of radical adducts, free radical metabolism, halothane (rat), 943
- Brain
 (RS)- α -amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors, multiple states, quantitative autoradiography (rat), 832
 cerebellar Purkinje neurons, permeation by calcium, kainate/ α -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors (rat), 603
 cortical neurons, competitive antagonism of glutamate receptor channels, substituted benzazepines, 1130
 developmental profile, metabotropic glutamate receptor mRNA (rat), 660
 dextrorphan binding, NMDA receptor-cation channel (rat), 134
 endothelin-converting enzyme, endothelial cells (rat), 399
 glycine site on NMDA receptor, improved affinity, kynurenic acid analogues (rat), 914
 heterogeneity of angiotensin II AT_2 receptors (rat), 290
 membranes, L-689,560 binding, NMDA receptor (rat), 923
 monoamine turnover, receptor binding, risperidone and ocaperidone (rat), 494
 RNA, hexachlorocyclohexanes, GABA receptors, 1107
 steroids and γ -aminobutyric acid receptors, poly(A)⁺ RNA (*Xenopus*), 89
 subtype of nicotinic cholinergic receptor, chronic nicotine treatment (rat), 31
 synaptic membranes, organophosphate interactions, NMDA receptors (rat), 750
- Bumetanide, chloride transport blockers, prevention, NMDA receptor-channel complex activation (rat), 217
- tert-Butyl hydroperoxide, killing of cultured hepatocytes, vitamin E effects, 1155
- Butyrylcholinesterase, interaction of tetrahydroaminoacridine (*Torpedo*), 412

C

Calcium

- cAMP and, competitive regulation, phospholipase C responses, 577
 cytosolic free, acetaminophen toxicity, hepatocytes (mouse), 665
 dihydropyridine Ca^{2+} antagonist receptor, ion dependence, mitochondria, 45
 entry into dissociated neurons, NMDA receptors, reduced and oxidized glutathione (rat), 308
 entry-mediated generation of inositol phosphates, activation of β -adrenergic receptors, myometrium (guinea pig), 509
 inositol 1,4,5-trisphosphate-induced release, dynamic control, 110
 luminal, sensitivity of Ca^{2+} stores, inositol 1,4,5-trisphosphate, 115
 neuropeptide Y-induced intracellular release, erythroleukemic cells (human), 767
 neuropeptide Y_1 subtype pharmacology, recombinantly expressed neuropeptide receptor, 817
 NMDA-evoked influx, inhibition by sodium nitroprusside (rat), 779
 permeation of kainate/ α -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors, cerebellar Purkinje neurons (rat), 603
 receptor-mediated entry, block of maitotoxin effects, SK&F 96365, 487
 thyroid cell adenylyl cyclase activity, carbachol-induced decrease (dog), 163

Calcium channel

- activators (S)-Bay K 8644 and FPL 64176, functional interactions, smooth muscle (rat), 599
 L-type, adenosine ligand (rabbit), 298
 regulation and subcellular location, nitrogen oxide synthases, RAW264.7 macrophages (mouse), 615
 voltage-dependent, Kupffer cells (rat), 435
- Calcium channel blocker, alteration of binding by cholesterol, membrane lipid bilayer (rabbit), 315
- Calcium current
 forskolin and an analog, cardiac myocytes (bullfrog), 880
 serotonin, 5-HT₄ receptors, atrial myocytes (human), 346
- Carbachol, -induced decrease, thyroid cell adenylyl cyclase activity (dog), 163
- Carbamylcholine, phencyclidine-sensitive ethidium binding, *Torpedo* acetylcholine receptor, 331
- Carbonic anhydrase, sulfonamides and, direct measurements, rate constants, 419
- Carcinogens, chemical, oxidation, lung microsomal cytochrome P-450 1A1 (human, rat), 856
- Cerebellum
 molecular cloning and characterization, major endothelin receptor subtype (pig), 465
 Purkinje neurons, permeation by calcium, kainate/ α -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors (rat), 603
- Chlorambucil, resistance, role of glutathione, glutathione S-transferase (mouse), 625
- Chloride, transport blockers, prevention, NMDA receptor-channel complex activation (rat), 217
- CHO cells, hydrogen peroxide-induced DNA damage, effects of L-histidine, 969
- CHO-K1 cells, stimulation of adenylyl cyclase by amylin, 894
- Cholesterol, alteration of binding of Ca^{2+} channel blockers, membrane lipid bilayer (rabbit), 315
- Cholinergic agonists, tyrosine hydroxylase induction, vasoactive intestinal polypeptide, adrenal chromaffin cells (bovine), 456
- Chrysophanol, topoisomerase II-mediated DNA cleavage activity, irreversibility, cleavable complex formation, 237
- Cisplatin, multidrug-resistant colon cancer cell line, glutathione S-transferase overexpression, thiol pools (human), 69
- Cobra α -toxin, phencyclidine-sensitive ethidium binding, *Torpedo* acetylcholine receptor, 331
- Cocaine, interactions with primary and secondary recognition sites, muscarinic receptors (human), 736
- Colonic neoplasms, multidrug-resistant, glutathione S-transferase overexpression, thiol pools (human), 69
- Corticosteroids, expression of cytochromes P450, cyclosporin A oxidase activity, hepatocytes (human), 1047
- Cyclic AMP
 calcium and, competitive regulation, phospholipase C responses, 577
 pathways of phosphoinositide hydrolysis, DDT₁-MF₂ cells, 587
- Cyclic GMP, -independent mechanism, inhibition of NMDA-evoked calcium influx, sodium nitroprusside (rat), 779
- Cyclosporin A oxidase, activity in hepatocytes, effect of corticosteroids, cytochromes P450 (human), 1047
- Cytochrome P-450
 corticosteroids, cyclosporin A oxidase activity, hepatocytes (human), 1047
 enzyme activities and cytochrome P-450IIC11, imprinting by peripubertal administration, testosterone in females (rat), 981
 isoenzyme CYP2E1, metabolic oxidation and toxification, N-methylformamide (mouse), 259
 microsomal, role of isozymes, metabolism of retinoic acid (rabbit), 427
- Cytochrome P-450 1A1
 lung microsomal, oxidation of chemical carcinogens (human, rat), 856

Cytochrome P-450 1A1—*continued*

- NADPH-cytochrome P450 reductase and, distribution in lung, 2,3,7, 8-tetrachlorodibenzo-*p*-dioxin (rabbit), 1039
- Cytochrome P-450 3A4, liver microsomal *N*-hydroxylation of dapsone (human), 975
- Cytochrome P-450 IIB1, monoclonal antibodies, recognition of different epitopes, human IIE1, 76
- Cytochrome P-450 IIE, pretranslational activation, ketosis induced by high fat diet (rat), 474
- Cytokinesis, selective inhibition, pseudopteroside, embryos (sea urchin), 631
- Cytosol, nucleosides, tolbutamide sensitivity, ATP-dependent K⁺ channel in pancreatic B cells (mouse), 480

D

- Dapsone, liver microsomal *N*-hydroxylation, cytochrome P-4503A4 (human), 975
- DDT₁-MF₂ cells, pathways of phosphoinositide hydrolysis, cyclic AMP, 587
- Dehydroepiandrosterone sulfotransferase
 - immunological characterization, liver and adrenal (human), 645
 - liver, molecular cloning and expression, cDNA (human), 865
- Delphinium brownii*, methyllycaconitine, blockade of nicotinic currents, hippocampal neurons (rat), 802
- 2'-Deoxyguanosine, carbocyclic analog, incorporation into DNA of herpes simplex virus, Hep-2 cells, 245
- 5'-Deoxythymidine, membrane permeation characteristics (human), 950
- Dextrorphan, binding in brain, NMDA receptor-cation channel (rat), 134
- Diacylglycerol, second messengers, quantitative analysis, platelets (human), 382
- Diacytosis, isoproterenol-initiated β -adrenergic receptor, cultured cells (human), 375
- 2,6-Diamino-*N*-([1-(1-oxotridecyl)-2-piperidinyl]methyl)hexanamide, novel inhibitor of protein kinase C, interaction, regulatory domain, 38
- Diaphorase, NADPH-dependent, induction, aortic smooth muscle and macrophages, 1163
- Dideoxyuridine 5'-monophosphate, membrane-permeable analogue, inhibition of HIV infection (human), 441
- Diet, high fat, pretranslational activation of cytochrome P450IIE, ketosis (rat), 474
- 1,5-(Diethylamino)piperidine, activation of NMDA receptor-associated polyamine site, 989
- Dihydropyrazole, insecticides, block of sodium channels, nerve (crayfish), 120
- Dihydropyridine, Ca²⁺ antagonist receptor, ion dependence, mitochondria, 45
- 1,4-Dihydropyridines, pharmacologic and radioligand binding studies, cardiac and vascular preparations (rat), 535
- Distamycin, -ellipticine hybrid molecule, DNA-binding properties, 845
 - DNA
 - binding properties, distamycin-ellipticine hybrid molecule, 845
 - helicase inhibition, anthracycline anticancer agents, 993
 - herpes simplex virus, carbocyclic analog of 2'-deoxyguanosine, Hep-2 cells, 245
 - hydrogen peroxide-induced damage and cytotoxicity, L-histidine, cultured mammalian cells, 969
- DNA, complementary, molecular cloning and expression, liver dehydroepiandrosterone sulfotransferase (human), 865
- DNA polymerase, inhibition by phosphorothioate oligonucleotides, antisense technology (human), 223
- DNA topoisomerase II, -mediated DNA cleavage activity, irreversibility, cleavable complex formation, 237
- Dopamine, D1 gene, molecular cloning and expression (monkey), 652
- Dorsal horn, neurons, activation of glutamate and glycine receptors, L-proline (rat), 793

- Drug delivery, lactosylated HDL, parenchymal liver cells (human), 404
- DT-diaphorase, activation of mitomycin C under hypoxia, 677
- DuP753

- angiotensin II receptor, guanine nucleotide-binding protein signaling pathways, 154
- sensitive angiotensin II receptor, modulation of angiotensin II binding affinity, polyvinyl sulfate, 809

E

- Eledoisin, binding to NK1 receptors, lung (guinea pig), 147
- Ellipticine, -distamycin hybrid molecule, DNA-binding properties, 845
- Embryo, selective inhibition of cytokinesis, pseudopteroside (sea urchin), 631
- Emodin, topoisomerase II-mediated DNA cleavage activity, irreversibility, cleavable complex formation, 237
- Endothelial cells, endothelin-converting enzyme, brain (rat), 399
- Endothelin
 - converting enzyme, endothelial cells, brain (rat), 399
 - receptor subtype, molecular cloning, cerebellum (pig), 465
- Endothelium
 - distribution of cytochrome P450 1A1, NADPH-cytochrome P450 reductase, lung (rabbit), 1039
 - vascular, inactivation of atrial natriuretic peptide, neutral endopeptidase-24.11 (rat, rabbit, human), 609
- Enterotoxin, *Escherichia coli* heat-stable, low affinity receptors, 1073
- Erythrocytes, membrane permeation characteristics, 5'-modified thymidine analogs (human), 950
- Erythroleukemic cells, neuropeptide Y-induced intracellular calcium release (human), 767
- Escherichia coli*, heat-stable enterotoxin, low affinity receptors, 1073
- Estramustine, two analogues and, molecular conformation, 569
- Ethanol, cerebellar granule cell exposure to, *N*-methyl-D-aspartate receptor function and, 1142
- Ethidium, phenylcyclidine-sensitive binding, *Torpedo* acetylcholine receptor, 331

F

- Fatty acid, ligand-operated synthesis, 4-series and 5-series leukotrienes, neutrophils (human), 757
- Fentanyl, molecular determinants of μ receptor recognition, 185
- Fibroblasts, distinct regulation, β_1 - and β_2 -adrenergic receptors (hamster), 542
- Flufenamic acid, chloride transport blockers, prevention, NMDA receptor-channel complex activation (rat), 217
- Forskolin
 - aminoalkylcarbamates, interaction with adenylyl cyclase (bovine), 360
 - analog and, calcium currents, cardiac myocytes (bullfrog), 880
 - noncompetitive inhibitor, nicotinic acetylcholine receptors, 908
- FPL 64176, (S)-Bay K 8644 and, functional interactions, smooth muscle (rat), 599
- Furosemide, chloride transport blockers, prevention, NMDA receptor-channel complex activation (rat), 217

G

- Gene, molecular cloning and expression, D1 dopamine receptor (monkey), 652
- Glia, primary cultures, loss of response to norepinephrine, β - versus α_2 -adrenergic receptors (rat), 688
- Glioma, NG108-15 neuroblastoma X glioma hybrid cells, guanine nucleotide-binding proteins, 822
- Glutamate
 - activation of NMDA receptor-associated polyamine site, 1,5-(diethylamino)piperidine, 989
 - competitive antagonism of receptor channels, substituted benzazepines, cortical neurons, 1130
 - receptor messenger RNA in brain, developmental profile (rat), 660

- L-Glutamate, NMDA and amino-3-hydroxy-5-methyl-4-isoxazolepropionate receptors, selectivity, amino acid transmitters (rat), 520
- Glutathione, reduced and oxidized, NMDA receptors, calcium entry into dissociated neurons (rat), 308
- Glutathione S-transferase
elevation of thiol pools, multidrug-resistant colon cancer cell line (human), 69
glutathione and, role in chlorambucil resistance (mouse), 625
human μ or α class, cellular sensitivity, cytotoxic agents, 230
- Glycine
activation of NMDA receptor-associated polyamine site, 1,5-(diethylamino)piperidine, 989
improved affinity and selectivity, kynurenic acid analogues, NMDA receptor from brain (rat), 914
- G proteins
activation of G_s and third intracellular loop, hydrophobic amino acids, 1061
coupling of somatostatin receptors, adenylyl cyclase, pituitary-derived AtT-20 cells, 452
heterogeneity of angiotensin II AT_2 receptors, brain (rat), 290
interaction with δ -opioid receptor, NG108-15 neuroblastoma X glioma hybrid cells, 822
-linked receptors, drug efficacy, 549
signaling pathways, angiotensin II receptor, DuP754, 153
specific antibodies against G_o isoforms, neuronal differentiation, 273
subtype-selective coupling to G_s , β_1 - and β_2 -adrenergic receptors (bullfrog), 889
- GTP-binding proteins, transfection of human 5-HT $_{1A}$ receptors, NIH-3T3 cells, 999
- Guanosine-5'-O-(2-thiodiphosphate), intracellular, receptor-mediated responses, sympathetic neurons (bullfrog), 527
- Guanosine triphosphate, regulation of binding, muscarinic receptor agonists, cardiac sarcolemma (dog), 168
- Guanylate cyclase, *Escherichia coli* heat-stable enterotoxin, low affinity receptors, 1073
- Guanylnucleotide, specificity for muscarinic receptor inhibitory coupling, cardiac adenylyl cyclase (dog), 177
- H**
- Halothane, free radical metabolism, radical adducts, detection in bile (rat), 943
- Heart
cloned human potassium channel, block by quinidine, mouse L cell line, 322
myocytes, effects of forskolin and an analog, calcium currents (bullfrog), 880
pharmacologic and radioligand binding studies, 1,4-dihydropyridines (rat), 535
sarcolemma, regulation of GDP and GTP binding, muscarinic receptor agonists (dog), 168
- Helicase, inhibition by anthracycline anticancer agents, 993
- Hemoglobin, synthesis in K-562 cells, 3'-azido-3'-deoxythymidine and its metabolite, 252
- Hepatocytes
acetaminophen toxicity, level, cytosolic free calcium (mouse), 665
cyclosporin A oxidase activity, effect of corticosteroids, cytochromes P450 (human), 1047
killing by *tert*-butyl hydroperoxide, vitamin E effects, 1155
primary culture, phase II metabolism, warfarin (rat), 209
- Hep-2 cells, incorporation of carbocyclic analog, 2'-deoxyguanosine, herpes simplex virus, 245
- Herpes, (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine, intracellular metabolism, 197
- Herpes simplex virus, incorporation of carbocyclic analog, 2'-deoxyguanosine, Hep-2 cells, 245
- Hexachlorocyclohexanes, γ -aminobutyric acid receptors, RNA from mammalian brain and retina, *Xenopus* oocytes, 1107
- Hippocampus
lack of apparent receptor reserve, postsynaptic 5-HT $_{1A}$ receptors (rat), 1066
neurons
blockade of nicotinic currents, methyllycaconitine (rat), 802
block by arcaïne, NMDA receptor responses (rat), 727
nicotinic acetylcholine currents (rat), 931
- L-Histidine, hydrogen peroxide-induced DNA damage and cytotoxicity, cultured mammalian cells, 969
- Histone, H1 gene expression, down-regulation, 1- β -D-arabinofuranosylcytosine, 64
- HIV-1
molecular characterization, resistance to non-nucleoside inhibitors, reverse transcriptase, 446
reverse transcriptase
allosteric inhibition, tetrahydroimidazo[4,5,1-*jk*][1,4]benzodiazepin-2(1*H*)-one, 203
interaction of inhibitors, 963
- Human immunodeficiency virus, inhibition, membrane-permeable deoxyuridine 5'-monophosphate analogue (human), 441
- Hydrogen peroxide, -induced DNA damage and cytotoxicity, L-histidine, cultured mammalian cells, 969
- 1-[(2-Hydroxyethoxy)methyl]-6-(phenylthio)thymine, interaction of tetrahydroimidazo[4,5,1-*jk*][1,4]benzodiazepin-2(1*H*)-one, HIV type 1 reverse transcriptase, 963
- (S)-1-[3-Hydroxy-2-(phosphonylmethoxy)propyl]cytosine, intracellular metabolism, 197
- Hypothalamic-pituitary-adrenal axis, increased glucocorticoid receptor gene promoter activity, after antidepressant treatment, 1016
- Hypoxia, activation of mitomycin C, DT-diaphorase, 677
- I**
- ICRF-187, ADR-529 Fe $^{3+}$ -anthracycline complex, direct complexation, 8
- Imprinting, peripubertal administration of testosterone, hepatic microsomal cytochrome P-450 enzyme activities (rat), 981
- Inositol 1,4,5-trisphosphate
-induced Ca $^{2+}$ release, dynamic control, 110
sensitivity of Ca $^{2+}$ stores, luminal Ca $^{2+}$, 115
- Inositol phosphates, Ca $^{2+}$ entry-mediated generation, activation of β -adrenergic receptors, myometrium (guinea pig), 509
- Insecticides, dihydropyrazole, block of sodium channels, nerve (crayfish), 120
- Insulin, -sensitizing agent, enhancement, adipocyte differentiation, 393
- Intercalator-alkylator, irreversible topoisomerase II-DNA complex, 237
- Ion, dependence, partially purified mitochondrial dihydropyridine Ca $^{2+}$ antagonist receptor, 45
- Isoflurane, acetylcholine receptor channels, 127
- Isoproterenol, -initiated β -adrenergic receptor diacytosis, cultured cells (human), 375
- Isoquinolinesulfonamide compounds, overcoming vinblastine resistance, Adriamycin-resistant leukemia cells, 1034
- Isradine, alteration of binding to membrane lipid bilayer, cholesterol (rabbit), 315
- K**
- Kainate, α -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors, permeation by calcium, cerebellar Purkinje neurons (rat), 603
- KB cells, regulation of P-glycoprotein phosphorylation, phorbol ester and protein kinase C inhibitors, 1008
- K-562 cells, hemoglobin synthesis, 3'-azido-3'-deoxythymidine and its metabolite, 252
- Ketosis, induction by high fat diet, pretranslational activation, cytochrome P450IIE (rat), 474

Kupffer cells

stimulation of monooxygenation and conjugation, liver transplantation (rat), 1149

voltage-dependent calcium channels (rat), 435

Kynurenic acid analogues, improved affinity and selectivity for glycine site, NMDA receptor, brain (rat), 914

L

L858051, forskolin and, effects on calcium currents, cardiac myocytes (bullfrog), 880

L-689,560, characterization of binding on NMDA receptor, brain membranes (rat), 923

Leukemia, myeloid, 1- β -D-arabinofuranosylcytosine treatment, transcription factor κ B, 60

Leukemia cells, Adriamycin-resistant, overcoming vinblastine resistance, isoquinolinesulfonamide compounds, 1034

Leukotrienes

biosynthesis inhibitors, 5-lipoxygenase-activating protein, 267

4-series and 5-series, ligand-operated synthesis, neutrophils (human), 757

synthesis inhibition, 5-lipoxygenase-activating protein binding assay (human), 873

Ligand

guanine nucleotide-binding regulatory protein-linked receptors, drug efficacy, 549

-operated synthesis of 4-series and 5-series leukotrienes, free fatty acid supply, neutrophils (human), 757

[35 S]sadopine, L-type calcium channels (rabbit), 298

single amino acid residue responsible for binding, β -adrenergic receptor antagonists, 5-HT_{1A} receptors, 695

Lipids

bilayer, cholesterol, Ca²⁺ channel blockers (rabbit), 315

cationic, cellular uptake and activity, phosphorothioate antisense oligonucleotides, 1023

Lipopolysaccharide, induction of NADPH-dependent diaphorase, nitric oxide synthase activity, smooth muscle, 1163

Lipoprotein, lactosylated HDL, carrier for site-specific delivery of drugs, liver parenchymal cells (human), 404

5-Lipoxygenase

-activating protein

binding assay, leukotriene synthesis inhibition (human), 873

target of novel hybrid, classes of leukotriene biosynthesis inhibitors, 267

Liver

dehydroepiandrosterone sulfotransferase

immunological characterization (human), 645

molecular cloning and expression, cDNA (human), 865

detection of radical adducts, free radical metabolism, halothane (rat), 943

parenchymal cells, lactosylated high density lipoprotein, carrier for site-specific delivery of drugs (human), 404

-specific asialoglycoprotein receptor RHL-1, late-stage spermatids (rat), 639

transplantation, stimulation, monooxygenation and conjugation (rat), 1149

Liver microsomes

cytochrome P-450 enzyme activities, imprinting by peripubertal administration, testosterone in females (rat), 981

N-hydroxylation of dapsone, cytochrome P-4503A4 (human), 975

role of isoenzymes, cytochrome P-450, metabolism of retinoic acid (rabbit), 427

Lung

binding to NK1 receptors, radioiodinated substance P, neurokinin A and eledoisin (guinea pig), 147

distribution of cytochrome P450 1A1, NADPH-cytochrome P450 reductase, 2,3,7,8-tetrachlorodibenzo-*p*-dioxin (rabbit), 1039

microsomal cytochrome P-450 1A1, role in oxidation, chemical carcinogens (human, rat), 856

M

Macrophages

induction of NADPH-dependent diaphorase, nitric oxide synthase activity, smooth muscle, 1163

RAW264.7, regulation and subcellular location, nitrogen oxide synthases (mouse), 615

Maitotoxin, effects blocked by SK&F 96365, 487

Mammalian cells, stable expression of active human renin, 53

MCF-7 cells, human μ or α class glutathione *S*-transferases, cellular sensitivity, cytotoxic agents, 230

6-Mercaptopurine, compared to mizoribine, T cell proliferation, purine ribonucleotide metabolism (human), 671

N-Methyl-D-aspartate

-evoked calcium influx, inhibition by sodium nitroprusside (rat), 779

single-channel kinetics, low doses of bicuculline, whole-cell currents (mouse), 900

receptor function, cerebellar granule cell exposure to ethanol and, 1142

N-Methylformamide, metabolic oxidation and toxification, cytochrome P450 isoenzyme CYP2E1, 259

Methyllycaconitine, blockade of nicotinic currents, hippocampal neurons (rat), 802

Microsomes, cytochrome P-450 1A1, oxidation of chemical carcinogens, lung (human, rat), 856

Mitochondria

dihydropyridine Ca²⁺ antagonist receptor, ion dependence, 45

stimulation of monooxygenation and conjugation, liver transplantation (rat), 1149

Mitomycin C, activation, hypoxia, DT-diaphorase, 677

Mizoribine, comparison of effects, T cell proliferation, purine ribonucleotide metabolism (human), 671

Monoamine, turnover, receptor binding, risperidone and ocaperidone (rat), 494

Monoclonal antibodies, recognition of different epitopes, rat cytochrome IIB1, reaction with human IIE1, 76

Monooxygenation, stimulation, conjugation, liver transplantation (rat), 1149

Multidrug resistance

colon cancer cell line, glutathione *S*-transferase overexpression, thiol pools (human), 69

overcoming vinblastine resistance, isoquinolinesulfonamide compounds, Adriamycin-resistant leukemia cells, 1034

regulation of P-glycoprotein phosphorylation, phorbol ester and protein kinase C inhibitors, KB cells, 1008

Muscarinic antagonists, structural basis of subtype selectivity, chimeric m2/m5 muscarinic receptors (human), 369

Muscle, smooth

cyclic AMP differentiation, phosphoinositide hydrolysis pathways, 587

functional interactions, (*S*)-Bay K 8644 and FPL 64176 (rat), 599

induction of NADPH-dependent diaphorase, nitric oxide synthase activity, 1163

trachea, relaxation, vasoactive intestinal peptide fragment (guinea pigs), 104

Mutagenesis, hydrophobic amino acids, third intracellular loop of β -adrenergic receptors, activation of G_s, 1061

Mycophenolic acid, compared to mizoribine, T cell proliferation, purine ribonucleotide metabolism (human), 671

Myocytes

atrial, serotonin increase in calcium current, 5-HT₄ receptors (human), 346

cardiac, effects of forskolin and an analog, calcium currents (bullfrog), 880

Myometrium, activation of β -adrenergic receptors, inhibition, Ca²⁺ entry-mediated generation of inositol phosphates (guinea pig), 509

N

- NADPH, -dependent diaphorase and nitric oxide synthase, induction, aortic smooth muscle and macrophages, 1163
- NADPH-cytochrome P450 reductase, cytochrome P450 1A1 and, distribution in lung, 2,3,7,8-tetrachlorodibenzo-*p*-dioxin (rabbit), 1039
- NAD(P)H:(quinone acceptor) oxidoreductase, DT-diaphorase, activation of mitomycin C, hypoxia, 677
- Na-H exchange, functional activation, mutant constructs, β -adrenergic receptor, 1056
- NCB-20 cells
platelet-activating factor, stimulation, phosphoinositide turnover, 281
regulation of signal transduction, purinergic receptor, 743
- N*-(2-Chloroethyl)-4-piperidinyl diphenylacetate, conversion to an aziridinium ion, interaction with muscarinic receptors, 718
- Nerve, slow voltage-dependent block of sodium channels, dihydropyrazole insecticides (crayfish), 120
- Neuroblastoma cells
functional reconstitution, 5-HT_{1C} receptors (mouse), 18
NG108-15 X glioma hybrid cells, 822
- Neurokinin, receptors, amino acid residues, substance P selectivity and specificity (rat), 1096
- Neurokinin-1
receptor isoforms, intracellular effector (human), 24
receptors, antagonists, species differences (rat), 772
- Neurokinin A, binding to NK1 receptors, lung (guinea pig), 147
- Neurons
cerebellar Purkinje, permeation by calcium, kainate/ α -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (rat), 603
chloride transport blockers, prevention, NMDA receptor-channel complex activation (rat), 217
cortical, competitive antagonism of glutamate receptor channels, substituted benzazepines, 1130
differentiation, specific antibodies, G_o isoforms, 273
dissociated, calcium entry, reduced and oxidized glutathione (rat), 308
dorsal horn, activation of glutamate and glycine receptors, L-proline (rat), 793
hippocampal
blockade of nicotinic currents, methyllycaconitine (rat), 802
block by arcaine, NMDA receptor responses (rat), 727
nicotinic acetylcholine currents (rat), 931
sympathetic, intracellular guanosine-5'-O-(2-thiodiphosphate), receptor-mediated responses (bullfrog), 527
- Neuropeptide Y
-induced intracellular calcium release, erythroleukemic cells (human), 767
Y₁ subtype pharmacology, recombinantly expressed neuropeptide receptor, 817
- Neurotransmitters
functionally relevant GABA_A receptors, equivalence, receptor affinity and potency, 1124
selectivity of amino acid transmitters, NMDA and amino-3-hydroxy-5-methyl-4-isoxazolepropionate receptors (rat), 520
- Neutral endopeptidase-24.11, inactivation of atrial natriuretic peptide, vascular endothelium (rat, rabbit, human), 609
- Neutrophils, ligand-operated synthesis, 4-series and 5-series leukotrienes, free fatty acid supply (human), 757
- Nicotine, subtype of nicotinic cholinergic receptor, brain (rat), 31
- Nicotinic currents, blockade by methyllycaconitine, hippocampal neurons (rat), 802
- Niflumic acid, chloride transport blockers, prevention, NMDA receptor-channel complex activation (rat), 217
- Nigrostriatal pathway, chronic selegiline administration, decreased tyrosine hydroxylase activity (rat), 839
- NIH-3T3 cells, transfection of human 5-HT_{1A} receptors, 999

- Nimodipine, alteration of binding to membrane lipid bilayer, cholesterol (rabbit), 315
- Nitrendipine, alteration of binding to membrane lipid bilayer, cholesterol (rabbit), 315
- Nitric oxide, -independent mechanism, inhibition of NMDA-evoked calcium influx, sodium nitroprusside (rat), 779
- Nitrogen oxide synthases, regulation and subcellular location, RAW264.7 macrophages (mouse), 615
- Norepinephrine, loss of response, β - versus α_2 -adrenergic receptors, primary glial cultures (rat), 688
- Nucleosides, cytosolic, tolbutamide sensitivity, ATP-dependent K⁺ channel in pancreatic B cells (mouse), 480

O

- Occiperidone, risperidone and, receptor binding, effects on monoamine turnover (rat), 494
- Okadaic acid, regulation of P-glycoprotein phosphorylation, phorbol ester and protein kinase C inhibitors, KB cells, 1008
- Oligonucleotides
phosphorothioate antisense
cellular uptake and activity, cationic lipids, 1023
inhibition of DNA polymerases (human), 223
- Oocytes
gg-aminobutyric acid A or C (*Xenopus*), 683
hexachlorocyclohexanes, GABA receptors (*Xenopus*), 1107
steroids and γ -aminobutyric acid receptors, poly(A)⁺ RNA, mammalian brain and retina (*Xenopus*), 89
structure, γ -less nicotinic acetylcholine receptor (*Xenopus*), 708
- Organophosphate, interactions at NMDA receptors, brain synaptic membranes (rat), 750

P

- Pancreas, B cells, cytosolic nucleosides and tolbutamide sensitivity, ATP-dependent K⁺ channel (mouse), 480
- Parenchymal cells, liver, lactosylated high density lipoprotein, carrier for site-specific delivery of drugs (human), 404
- Parkinson's disease, chronic selegiline administration, decreased tyrosine hydroxylase activity, nigrostriatal pathway (rat), 845
- pBC 264, probe for studying cholecystokinin receptors (rat), 1089
- PC12 cells
adenosine A_{2A} receptors (rat), 352
neuronal "nucleotide" receptor, phospholipase C and D, ATP analogues and UTP, 561
- Peptide, nonpeptide angiotensin II antagonists and, receptor interaction, 1081
- Pertussis toxin
heterogeneity of angiotensin II AT₂ receptors, brain (rat), 290
platelet-activating factor, phosphoinositide turnover, neurohybrid NCB-20 cells, 281
- P-glycoprotein
overcoming vinblastine resistance, isoquinolinesulfonamide compounds, Adriamycin-resistant leukemia cells, 1034
regulation of phosphorylation, phorbol ester and protein kinase C inhibitors, KB cells, 1008
- Phencyclidine, -sensitive ethidium binding, *Torpedo* acetylcholine receptor, 331
- Phorbol ester, protein kinase C inhibitors and, regulation of P-glycoprotein phosphorylation, KB cells, 1008
- Phosphodiesterase, thyroid cell adenylyl cyclase activity, carbachol-induced decrease (dog), 163
- Phosphoinositide
pathways, cyclic AMP differentiation, DDT₁-MF₂ cells, 587
turnover, platelet-activating factor, neurohybrid NCB-20 cells, 281
- Phospholipase C
competitive regulation of responses, cAMP and calcium, 577
neuronal "nucleotide" receptor, stimulation by ATP analogues and UTP, PC12 cells, 561

Phosphorothioate

- antisense oligonucleotides, cellular uptake and activity, cationic lipids, 1023
- oligonucleotides, inhibition of DNA polymerases, antisense technology (human), 223

Photolabeling, photoactivable agonist, nicotinic acetylcholine receptor, 1100

Pioglitazone, insulin-sensitizing agent, enhancement, adipocyte differentiation, 393

Piretanide, chloride transport blockers, prevention, NMDA receptor-channel complex activation (rat), 217

Pituitary, -derived AtT-20 cells, SRIF receptor/adenylyl cyclase coupling, 452

Platelet-activating factor, stimulation of phosphoinositide turnover, neurohybrid NCB-20 cells, 281

Platelets

- novel inhibitor of protein kinase C, regulatory domain, NPC 15437, 38
- quantitative analysis, diacylglycerol second messengers (human), 382

Polyamine

- NMDA receptor-associated site, activation, 1,5-(diethyl-amino)piperidine, 989
- recognition site, mono-/di-/triamines, effects on NMDA receptor complex, 785

Polyvinyl sulfate, allosteric interaction, modulation, angiotensin II binding, 809

Potassium channel

- ATP-dependent, cytosolic nucleosides and tolbutamide sensitivity, pancreatic B cells (mouse), 480
- cloned human cardiac, block by quinidine, mouse L cell line, 322

L-Proline, activation of glutamate and glycine receptors, dorsal horn neurons (rat), 793

Protein kinase C

- inhibition of GABA_A receptor, desensitization, 1116
- inhibitors

- 2,6-diamino-N-([1-(1-oxotridecyl)-2-piperidinyl]methyl)hexanamide, regulatory domain, 38
- regulation of P-glycoprotein phosphorylation, KB cells, 1008
- staurosporine, kinetic analysis (rat), 387

- platelet-activating factor, phosphoinositide turnover, neurohybrid NCB-20 cells, 281

Pseudopterolide, selective inhibition of cytokinesis, embryos (sea urchin), 631

Purine ribonucleotide, metabolism and T cell proliferation, effects of mizoribine, azathioprine (human), 671

Q

Quinidine, block of cloned human cardiac potassium channel, mouse L cell line, 322

Quinoxaline, derivatives, structure-activity relationships (*Xenopus*), 337

R

Receptors

acetylcholine

- phencyclidine-sensitive ethidium binding (*Torpedo*), 331
- single-channel currents, effects of isoflurane, 127

adenosine A_{2A}, striatum and PC12 cells (rat), 352 γ -aminobutyric acid

- hexachlorocyclohexanes, RNA from mammalian brain and retina, 1107

- steroids and, poly(A)⁺ RNA (*Xenopus*), 89

 γ -aminobutyric acid A or C, *Xenopus* oocytes, 683

- (*RS*)- α -amino-3-hydroxy-5-methylisoxazole-4-propionic acid, quantitative autoradiography, brain (rat), 832

- β_1 - and β_2 -adrenergic, distinct regulation, fibroblasts (hamster), 542
- angiotensin II

DuP753, guanine nucleotide-binding protein signaling, 154

- modulation of binding affinity, polyvinyl sulfate, 809

angiotensin II AT₂, heterogeneity, brain (rat), 290

- binding and effects on monoamine turnover, risperidone and ocaperidone, brain (rat), 494

chimeric m2/m5 muscarinic, subtype selectivity, muscarinic antagonists (human), 369

cholecystokinin, [³H]pBC 264 probe (rat), 1089

- dihydropyridine Ca²⁺ antagonist, ion dependence, mitochondria, 45

dopamine D1, molecular cloning, gene expression (monkey), 652

- endothelin subtype, molecular cloning, cerebellum (pig), 465

GABA_A

- equivalence between receptor affinity, potency, 1124

- inhibition by protein kinase C activation, desensitization, 1116

- glucocorticoid, gene promoter activity, after antidepressant treatment, 1130

glutamate

- competitive antagonism by substituted benzazepines, cortical neurons, T21

- messenger RNA, developmental profile in the brain (rat), 660

- glutamate and glycine, activation by L-proline, dorsal horn neurons (rat), 793

- guanine nucleotide-binding regulatory protein-linked, drug efficacy, 549

- heterogeneity, tissue response as a functional discriminator, Schild regressions, 699

5-HT_{1A}

- single amino acid residue, binding of β -adrenergic receptor antagonists, 695

- transfection, NIH-3T3 fibroblasts, 999

5-HT_{1B}, species homologue, human 5-HT receptor (rat), 1

- 5-HT_{1C}, functional reconstitution, N1E-115 cells (mouse), 18

- 5-HT₄, serotonin increase in calcium current, atrial myocytes (human), 346

- interaction, peptide and nonpeptide angiotensin II antagonists, 1081

- kainate/ α -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid, permeation by calcium, cerebellar Purkinje neurons (rat), 603

- lack of reserve, postsynaptic 5-HT_{1A} receptors, hippocampal membranes (rat), 1066

- γ -less nicotinic acetylcholine, structure of (*Xenopus*), 708

- low affinity, *Escherichia coli* heat-stable enterotoxin, 1073

- mediated calcium entry, block of maitotoxin effects, SK&F 96365, 487

- mediated responses in sympathetic neurons, intracellular guanosine-5'-O-(2-thiodiphosphate) (bullfrog), 527

N-methyl-D-aspartate

- block by arcaine, hippocampal neurons (rat), 727

- calcium entry into dissociated neurons, glutathione (rat), 308

- chloride transport blockers, prevention of activation (rat), 217

- dextrorphan binding, brain (rat), 134

- effects of mono-/di-/triamines, polyamine recognition site, 785

- kynurenic acid analogues, glycine site in brain (rat), 914

- L-689,560 binding, brain membranes (rat), 923

- organophosphate interactions, brain synaptic membranes (rat), 750

- quinoxaline derivatives, structure-activity relationships (*Xenopus*), 337

- spermine actions, single-channel currents (rat), 83

- mu*, molecular determinants, fentanyl class of compounds, 185

muscarinic

- conversion of N-(2-chloroethyl)-4-piperidinyl diphenylacetate, aziridinium ion, 718

- guanylnucleotide, cardiac adenylate cyclase (dog), 177

- interactions of cocaine, primary and secondary recognition (human), 736

- regulation of GDP and GTP binding, cardiac sarcolemma (dog), 168

- neurokinin, amino acid residues, substance P selectivity and specificity (rat), 1096
- neurokinin-1
antagonists, species differences (rat), 772
intracellular effector (human), 24
- neuronal "nucleotide", phospholipase C and D, PC12 cells, 561
- neuropeptide, Y₁ subtype pharmacology, 817
- nicotinic acetylcholine
currents, postnatal hippocampal neurons (rat), 931
forskolin, noncompetitive inhibitor, 908
photoactivable agonist, 1100
- nicotinic cholinergic, chronic nicotine treatment, brain (rat), 31
- NMDA, polyamine site activation, 1,5-(diethylamino)piperidine, 989
- NMDA and amino-3-hydroxy-5-methyl-4-isoxazolepropionate, selectivity, amino acid transmitters (rat), 520
- nucleotide-induced enhancement, tolbutamide sensitivity (mouse), 480
- opioid δ , guanine nucleotide-binding proteins, hybrid cells, 822
- purinergic, regulation of signal transduction, NCB-20 cells, 743
- RHL-1, late-stage spermatids (rat), 639
- somatostatin, G proteins, coupling to adenylyl cyclase in pituitary-derived AtT-20 cells, 452
- β - versus α_2 -adrenergic, loss or response to norepinephrine, primary glial cultures (rat), 688
- Renin, stable expression in mammalian cells, 53
- Retina
RNA, hexachlorocyclohexanes, GABA receptors, 1107
steroids and γ -aminobutyric acid receptors, poly(A)⁺ RNA (*Xenopus*), 89
- Retinoic acid, metabolism, role of isozymes, microsomal cytochrome P-450 (rabbit), 427
- Reverse transcriptase
HIV type 1, inhibitors, 963
non-nucleoside inhibitors, resistance, molecular characterization of HIV-1, 446
- Risperidone, ocaperidone and, receptor binding, effects on monoamine turnover (rat), 494
- RNA
helicase inhibition, anthracycline anticancer agents, 993
mammalian brain and retina, hexachlorocyclohexanes, GABA receptors, 1107
poly(A)⁺, steroids and γ -aminobutyric acid receptors (*Xenopus*), 89
structure of γ -less nicotinic acetylcholine receptor, *Xenopus* oocytes, 708
- RNA, messenger
decreased tyrosine hydroxylase activity, chronic selegiline administration, nigrostriatal pathway (rat), 839
H1 histone, down-regulation, 1- β -D-arabinofuranosylcytosine, 64
increased glucocorticoid receptor gene promoter activity, after antidepressant treatment, 1016
metabotropic glutamate receptor, developmental profile, brain (rat), 660
- RNase H, inhibition by phosphorothioate oligonucleotides, antisense technology (human), 223

S

- Sadopine, ligands for L-type calcium channels (rabbit), 298
- Sarcolemma, cardiac, regulation of GDP and GTP binding, muscarinic receptor agonists (dog), 168
- Schild regressions, tissue response as a functional discriminator, receptor heterogeneity, 699
- Selegiline, chronic administration, tyrosine hydroxylase activity and mRNA, nigrostriatal pathway (rats), 839
- Serotonin, increased calcium current, 5-HT₄ receptors, atrial myocytes (human), 346
- SK-31690, topoisomerase II-mediated DNA cleavage activity, irrevers-

- ibility, cleavable complex formation, 237
- SK&F 96365, block of maitotoxin effects, 487
- Sodium channel, slow voltage-dependent block, crayfish nerve, dihydropyrazole insecticides, 120
- Sodium nitroprusside, inhibition of NMDA-evoked calcium influx, nitric oxide- and cGMP-independent mechanism (rat), 779
- Species differences, antagonists, neurokinin-1 receptors (rat), 772
- Spermatids, late-stage, expression, "liver-specific" asialoglycoprotein receptor RHL-1 (rat), 639
- Spermine, multiple actions on NMDA receptor, single-channel currents, cortical neurons (rat), 83
- Staurosporine, protein kinase C inhibition, kinetic analysis (rat), 387
- Steroids, γ -aminobutyric acid receptors, poly(A)⁺ RNA, mammalian brain and retina (*Xenopus*), 89
- Striatum, adenosine A_{2A} receptors (rat), 352
- Substance P
radioiodinated, binding to NK1 receptors, lung (guinea pig), 147
selectivity and specificity, amino acid residues, neurokinin receptors (rat), 1096
- Sulfonamides, carbonic anhydrase and, direct measurements, rate constants, 419
- SV40 large T antigen, helicase inhibition, anthracycline anticancer agents, 993
- Synapse, selectivity of amino acid transmitters, NMDA and amino-3-hydroxy-5-methyl-4-isoxazolepropionate receptors (rat), 520
- Synaptic potentials, quinoxaline derivatives, structure-activity relationships (*Xenopus*), 337

T

- T cells, proliferation, effects of mizoribine, purine ribonucleotide metabolism (human), 671
- Testosterone, peripubertal administration, hepatic microsomal cytochrome P-450 enzyme activities, imprinting (rat), 981
- Tetrahydroaminoacridine, interaction with acetylcholinesterase, butyrylcholinesterase (*Torpedo*), 412
- Tetrahydroimidazo[4,5,1-*jk*][1,4]benzodiazepin-2(1*H*)-one
allosteric inhibition of HIV-1 reverse transcriptase, 203
interaction with 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine, HIV type 1 reverse transcriptase, 963
- Thiol, pools, overexpression of glutathione S-transferase, multidrug-resistant colon cancer cell line (human), 69
- Thymidine
dideoxyribose analogs, nonfacilitated membrane permeability, desolvation energy, 957
5'-modified analogs, membrane permeation characteristics (human), 950
- Thyroid, cell adenylyl cyclase activity, carbachol-induced decrease (dog), 163
- Torpedo*, forskolin as noncompetitive inhibitor, nicotinic acetylcholine receptors, 908
- Trachea, smooth muscle relaxation, vasoactive intestinal peptide fragment (guinea pigs), 104
- Transcription factor κ B, 1- β -D-arabinofuranosylcytosine treatment, human KG-1 myeloid leukemia cells, 60
- Transplantation, liver, stimulation, monooxygenation and conjugation (rat), 1149
- Triamines, effects on NMDA receptor complex, polyamine recognition site, 785
- Tyrosine hydroxylase
decreased activity and mRNA, chronic selegiline administration, nigrostriatal pathway (rat), 839
induction by cholinergic agonists, vasoactive intestinal polypeptide, adrenal chromaffin cells (bovine), 456

U

- Ultrastructure, distribution of cytochrome P450 1A1, NADPH-cytochrome P450 reductase, lung (rabbit), 1039

1186 Subject Index

UTP, neuronal "nucleotide" receptor, phospholipase C and D, PC12 cells, 561

V

Vasoactive intestinal peptide, fragment, trachea smooth muscle relaxation (guinea pigs), 104

Vasoactive intestinal polypeptide, tyrosine hydroxylase induction, cholinergic agonists, adrenal chromaffin cells (bovine), 456

Vinblastine, overcoming resistance, isoquinolinesulfonamide com-

pounds, Adriamycin-resistant leukemia cells, 1034

Vitamin E, killing of cultured hepatocytes, *tert*-butyl hydroperoxide, 1155

Voltage, -dependent calcium channels, Kupffer cells (rat), 435

W

Warfarin, phase II metabolism, primary culture, adult hepatocytes (rat), 209

Copyright © 1992 by the American Society for
Pharmacology and Experimental Therapeutics

INSTRUCTIONS TO AUTHORS

Molecular Pharmacology will publish the results of investigations that contribute significant new information on drug action or selective toxicity at the molecular level. The term "drug" is defined broadly to include chemicals that selectively modify biological function.

Suitable papers are those that describe applications of the methods of biochemistry, biophysics, genetics, and molecular biology to problems in pharmacology or toxicology. Also suitable are reports of fundamental investigations which, although not concerned directly with drugs, nevertheless provide an immediate basis for further study of the molecular mechanism of drug action. Observations of phenomena that shed no light upon underlying molecular interactions are not appropriate for publication. Comparative studies, such as those involving drug-receptor or drug-enzyme interactions that already have been well characterized in other types of cells or tissues, also are inappropriate for publication unless they contribute significant new insight into mechanisms.

Molecular Pharmacology has adopted a uniform policy for evaluation of manuscripts utilizing molecular modeling. Key aspects of content that determine suitability and eventual acceptance include: use of modeling technology to generate predictions concerning new molecules, modeling studies that offer significant new insights into the mechanism of actions of drugs, and inclusion of experimental data that support the predictions of molecular modeling. It is not necessary that each aspect be reflected in every manuscript; however, manuscripts that are purely theoretical in nature or that simply generate structural predictions without correlating these to drug action or new biological data will be returned as unsuitable for publication.

Specific areas of interest include: identification and characterization of receptors for hormones, growth factors, neurotransmitters, toxins, and other drugs; analysis of receptor response pathways; drug effects on metabolic pathways, biosynthesis and degradation of macromolecules, and cellular regulatory mechanisms; analysis of drug-receptor and drug-enzyme interactions; effects of drugs on structure and properties of macromolecules and membranes; relationships between drug structure and activity; molecular mechanisms of drug metabolism; distribution and transport between biological compartments; molecular mechanisms of chemical mutagenesis, carcinogenesis, and teratogenesis; and molecular mechanisms of selective toxicity, drug allergy, and pharmacogenetics.

Page charges. Authors will be billed at the rate of \$40.00 per page after the paper has been published. It is expected that the page charge will be paid if funds are available for that purpose from the author's institution or from the sponsor of this research. Payment of the charge is not a condition for publication. In case of personal financial hardship, page charges will be waived. Neither the editors nor the reviewers will have knowledge as to who has paid the charge, and this payment always will be considered entirely voluntary.

Submission of manuscript. Manuscripts are published in English only and should be sent to **Dr. T. Kendall Harden, Editor, *Molecular Pharmacology*, CB 7368, Department of Pharmacology, University of North Carolina School of Medicine, Chapel Hill, North Carolina 27599-7368, U. S. A.**

The expenses associated with the review of manuscripts submitted to *Molecular Pharmacology* and other ASPET-sponsored journals that are devoted to publishing original research articles have escalated dramatically in recent years because of ever-increasing costs of postage, supplies, and other office expenses, and the growing number of manuscripts submitted for publication. Thus, it has become necessary for ASPET to follow the example of several other scientific societies which have instituted uniform manuscript handling fees. *Therefore, all manuscripts must be accompanied either by a check for \$40 (in U. S. funds drawn on a U. S. bank payable to ASPET) or by a validated purchase order from the authors' institution.* The review process for submitted manuscripts will be delayed until the manuscript handling fee or purchase order is received in the Editor's office. If submission of the manuscript handling fee entails a personal financial hardship to the author(s), the fee will be waived. In that event, the author(s) should submit a request for waiver of the fee when the manuscript is submitted.

Manuscripts should be typewritten double-spaced with ample margins on one side of the paper, 8½ × 11 inches (ca. 215 × 280 mm). Submit four complete copies of the manuscript and four copies of each figure, plus one original drawing or photograph of each figure. Each half-tone figure requires four original drawings or photographs. All pages should be numbered consecutively beginning with the title page. Limit your reference listings to the minimal

number required to document the manuscript adequately. In most instances 30 references or fewer should suffice.

Under usual circumstances reviewers will be instructed to return only their comments to the editorial office and to destroy manuscripts after a final decision on their acceptability has been made. Original drawings and single copies of manuscripts not accepted for publication will be returned to the authors upon request.

It is understood that the manuscripts and the results they contain will not have been published previously and are not being submitted elsewhere. If the submitted manuscript utilizes or makes bibliographic reference to articles in press, copies should be included with the manuscript. Manuscripts are accepted for review with the understanding that all persons listed as authors have given their approval for the submission of the paper; further, that any person cited as a source of personal communications has approved such citation. Written authorization may be required at the Editor's discretion. Articles and any other material published in *Molecular Pharmacology* represent the opinions of the author(s) and should not be construed to reflect the opinions of the Editor(s) and the Publisher. If and when a manuscript is published, it will become the sole property of the Journal.

Authors submitting a manuscript do so on the understanding that if it is accepted for publication, copyright in the article, including the right to reproduce the article in all forms and media, shall be assigned exclusively to the Society for Pharmacology and Experimental Therapeutics. No reasonable request by the author for permission to reproduce any of his or her contributions to the journal will be refused.

Accelerated Communications. In order to provide a mechanism for rapid publication of novel experimental findings of unusual and timely significance, manuscripts will be accepted for consideration as Accelerated Communications. Accelerated Communications are not intended for publication of preliminary results. Manuscripts submitted under this category should present novel results that are clearly documented and should make a conceptual advance in their

field. They will be reviewed by the same criteria applied to regular papers in *Molecular Pharmacology*. The manuscript should be accompanied by a transmittal letter briefly outlining the significance of the work and providing a list of at least three scientists who would be appropriate reviewers.

Accelerated Communications will be reviewed as rapidly as possible with the aim of reaching an editorial decision within four weeks of receipt of the manuscript. It is expected that Accelerated Communications which are accepted will be published in essentially the form submitted. Manuscripts accepted without revision will be published within four to five months of initial receipt. Manuscripts accepted with a requirement for minor revisions will be published two or three months following receipt of a suitably revised version.

All manuscripts that require major revisions or that do not fit the criteria for Accelerated Communications will be returned to authors for revision and further consideration as a regular paper. Such manuscripts will retain the original submission date if revised versions are received in a timely manner.

Accelerated Communications may be submitted in the same style as regular manuscripts. Results and Discussion may be combined at the discretion of the authors. Manuscripts must not exceed five printed pages in the journal. This corresponds approximately to 25 double-spaced typewritten pages (1-inch margins) including all components of the manuscript and counting each figure as a page of typewritten text. Manuscripts that are judged to be too long will be considered as regular papers.

Organization and style of manuscripts. The policy of the Journal is to allow authors maximum freedom in organizing and presenting their material, and in expressing their ideas, provided only that clarity and conciseness are achieved. For most manuscripts, the most suitable format is: (1) Summary, (2) Introduction, (3) Materials and Methods, (4) Results, and (5) Discussion.

Certain conventions must be observed. Chemical and mathematical formulas and abbreviations should follow the *Instructions to Authors of the Journal of Biological Chemistry* (Vol. 261, pp. 1-11, January 10, 1986). Drugs must be referred to by their generic or chemical names throughout the text, but may be identified by trade name in parentheses or a footnote. The systematic name and number given by the Commission on Enzymes of the International Union of Biochemistry should be included for each enzyme of importance in a paper, at the point in the Summary or Introduction where the enzyme is first mentioned. The use of abbreviations should be minimized and abbreviations avoided in the Summary. All essential abbreviations should be defined in a single footnote when first introduced. Abbreviations of journal names should conform to the style of *Biological Abstracts*. References to papers that have been accepted for publication, but have not appeared, should be cited like other references with the abbreviated name of the journal followed by the words "in press." Copies of such papers should be sent whenever the findings described in them have a direct bearing on the paper being submitted for publication. "Personal Communications" and "Unpublished Observations" should be cited in footnotes to the text and should not be included in the reference list.

A manuscript should include the following, in the order listed: (1) Title. Numbered footnotes to the title should be avoided; acknowledgment of financial support should be given in an unnumbered footnote to the title. (2) Names of authors, their laboratory and institution. (3) A running title, not exceeding 60 characters and spaces. (4) Summary. (5) Text. Footnotes should be referred to by superscript numbers and references by numbers in parentheses. (6) References, numbered according to order of citation in the text, including title and complete pagination. Examples: 1. Goren, J. H., L. G. Bauge, and W. Vale. Forces and structural limitations of binding of thyrotropin-releasing receptor: the pyroglutamic acid moiety. *Mol. Pharmacol.* 13:606-614 (1977). 2. Chernow, B., and J. T. O'Brien. Overview of catecholamines in selected endocrine systems, in *Norepinephrine* (M. G. Ziegler and C. R. Lake, eds.). Williams and Wilkins, Baltimore, 439-449 (1984). 3. Snedecor, G. W., and W. G. Cochran. *Statistical Methods*. Iowa State University Press, Ames (1967). (7). Footnotes, numbered according to order of appearance in the text. (8) Tables. (9) Figures. (10) Legends to figures. (11) Name and address of person to receive galley proof.

Tables. These should be numbered with arabic numerals and designed to fit the single-column width of the full-page width. Every table should have an explanatory title and sufficient experimental detail in a paragraph following the title to be intelligible without references to the text (unless the procedure is given in the Methods section, or under another table or figure). Footnotes to tables should appear beneath the tables themselves and should be designated by lower-case italic superscript letters, *a*, *b*, *c*, etc.

Figures. These should be numbered with arabic numerals. Each of the four manuscript copies should contain all of the figures. Only the original set need be of quality suitable for reproduction except in the case of half-tones, which require four sets of photographs or original drawings. These should be unmounted glossy photographs (or original India-ink drawings). Usually figures will be reduced to one column width (85 mm) and all numbers *after* such reduction should be at least 1.5 mm high. The figures must be ready, in all respects, for direct reproduction: no lettering or other art work will be done by the publisher. If symbols are not explained on the face of the figure, only standard characters, of which the printer has type, may be used ($\times$, $\circ$, $\bullet$, $\square$, $\blacksquare$, $\triangle$, $\blacktriangle$, $\odot$). The back of each photograph should bear its number, and the legend TOP at the appropriate edge. The list of legends for the figures should give captions and sufficient experimental detail, as required for tables.

Page proof. Authors will be billed for substantial changes in page proof. The Editors are very much interested in having accepted contributions appear in the earliest possible issue of the Journal, and therefore request that galley proof be returned within 24 hours after its receipt. In exceptional cases, a "Note added in proof" may be attached and will be published if the Editor approves.

Reprints and page charges. An order form for reprints as well as information on the estimation of page charges will be mailed with galley proof. Please direct questions on reprints, page charges, or other business matters to Kay Croker, Executive Officer, American Society for Pharmacology and Experimental Therapeutics, 9650 Rockville Pike, Bethesda, Md. 20814. Telephone (301)530-7060.

One of the top ranking journals in the field

PHARMACOLOGICAL REVIEWS

*Official Publication of the American Society for
Pharmacology and Experimental Therapeutics, Inc.*

Robert E. Stitzel, PhD, Editor
West Virginia University Medical Center

PHARMACOLOGICAL REVIEWS is a showcase for important review articles in your field, featuring longer papers on topics of high current interest. Recent articles include:

**The Physiology and Pharmacology of
Corticotropin-Releasing Factor**

M.J. OWENS and C.B. NEMEROFF

**Structure and Function of
Alpha-Adrenoceptors**

R. RUGGOLO

**Serotonin and Neuropsychiatric Disorders:
Implications for the Development of New
Psychotherapeutic Agents**

CAROLE WILMOT

PHARMACOLOGICAL REVIEWS continues to publish the important, longer papers of interest to pharmacologists, physiologists, toxicologists, and biological chemists. No library serving the pharmacologist should be without a subscription.

To subscribe to **PHARMACOLOGICAL REVIEWS**, use the coupon below. Or for even faster service — CALL TOLL-FREE 1-800-638-6423 from anywhere in the U.S. or Canada.

Yes, enter my subscription to **Pharmacological Reviews**. (Quarterly)

- ☐ Individual \$55/year
☐ Institutional \$98/year
☐ In-training* \$40/year

*Institution/status _____
(Add \$15 outside U.S.)

Avoid future rate increases and ensure uninterrupted service, enter your subscription for:

- ☐ 3 years ☐ 2 years ☐ 1 year
☐ New subscription ☐ Renewal

Name _____

Address _____

City/State/Zip _____

Payment options:

- ☐ Check enclosed (payable to Williams & Wilkins)
☐ Bill me ☐ Charge: ☐ American Express
☐ MasterCard ☐ VISA

Card # _____ Exp. date _____

Signature or P.O. # _____

Maryland subscribers, please add 5% sales tax.
California subscribers, please add 8% sales tax.
Canadian subscribers, please add 7% GST. Subscriptions from outside the U.S. must be prepaid in U.S. dollars only. Rates valid until October 31, 1992. Please allow 10 weeks for delivery of your first issue. Surface mail to countries outside the U.S. may take up to 16 weeks. Airmail rates available upon request.




Williams & Wilkins
P.O. Box 23291
Baltimore, MD 21203-9990
Broadway House
2-6 Fulham Broadway
London SW6 1AA England

Return order form to Williams & Wilkins, or call toll-free 1-800-638-6423 from anywhere in the U.S. or Canada.

Need shelf space?

Williams & Wilkins is your source for back issues of this journal in microform.

Free Up 98% Of
Your Shelf Space With
Microform Conversion



MICROFILM editions are available for this journal direct from the publisher. Many Williams & Wilkins journals as well as those journals distributed by the Publishing Services Division of Waverly, Inc., are also available for a single volume year or on a standing order basis.

For ordering information: Write to the address below or call **TOLL FREE 1-800-638-6423**. In Maryland call **1-800-638-4007**.

☐ **Please send me microform back issue ordering information for**

Journal Name _____

Name _____

Title _____

Address _____

City/State/Zip _____

Mail to:

Williams & Wilkins

Microform Sales
Attention: Yvonne Hahn
428 East Preston Street
Baltimore, MD 21202

or

The Broadway Centre
2-6 Fulham Broadway
London SW6 1AA England

Formats available:

- 16-mm reel
- 35-mm reel
- 16-mm cartridge (3M or Kodak)
- positive or negative film

Previous Editors

- 1965** Avram Goldstein, *Editor*. Stanford University.
- 1968** Paul Talalay, *Editor*; Donald S. Coffey, *Associate Editor*. Johns Hopkins University.
- 1971** Steven E. Mayer, *Editor*, Palmer W. Taylor, *Associate Editor*. University of California at San Diego.
- 1975** George I. Drummond, *Editor*; H. Joseph Goren, *Associate Editor*. University of Calgary.
- 1978** Norman Kirschner, *Editor*; Theodore A. Slotkin, *Associate Editor*. Duke University.
- 1983** Joel G. Hardman, *Editor*; Lee Limbird, F. Peter Guengerich, *Associate Editors*. Vanderbilt University.
- 1986** William A. Catterall, *Editor*; Joseph A. Beavo, Mont R. Juchau, Neil M. Nathanson, Daniel R. Storm, Frank F. Vincenzi, *Associate Editors*. University of Washington, Seattle.

INFORMATION TO SUBSCRIBERS

MOLECULAR PHARMACOLOGY is published monthly, two volumes a year, beginning in January & July. Instructions to Authors will be found in every issue.

Correspondence concerning business matters should be addressed to Williams & Wilkins, 428 East Preston St., Baltimore, Maryland 21202-3993 U.S.A.

Correspondence regarding editorial matters should be addressed to the Editor, Dr. T. Kendall Harden, CB 7368, Department of Pharmacology, University of North Carolina School of Medicine, Chapel Hill, NC 27599-7368.

Annual Subscription Rates—U. S. A. AND POSSESSIONS: personal, \$100.00; institutional, \$210.00, single copy, \$18.00. FOREIGN: personal, \$130.00; institutional, \$240.00; single copy, \$21.00. (Prices subject to change.) Institutional (multiple reader) rate applies to libraries, schools, hospitals, clinics, group practices, and federal, commercial, and private institutions and organizations. Foreign subscribers who wish to have issues sent by air mail may inquire of the publisher for the additional cost. The GST Tax Number for Canadian subscribers is 123394371.

Change of address: Publisher must be notified 60 days in advance. Journals undeliverable because of incorrect address will be destroyed. Duplicates can be obtained (if available) from the publisher at the regular price of single issues.

New subscriptions are entered to begin with the next issue to publish unless instructed otherwise by the subscriber. Subscriptions run for a 12-month period.

To avoid a break in your series, subscriptions should be renewed promptly. The publisher cannot guarantee to supply back issues on belated renewals.

Reprints of individual articles are available *only* from authors.

Microfilm. For availability, inquire of Williams & Wilkins.

Williams & Wilkins, Baltimore, MD 21202-3993 U. S. A.